

Review



Cite this article: Francavilla C, O'Brien CS. 2022 Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer. *Open Biol.* **12**: 210373. <https://doi.org/10.1098/rsob.210373>

Received: 11 December 2021
Accepted: 20 January 2022

Subject Area:
cellular biology

Keywords:
breast cancer, fibroblast growth factor receptor, signalling, FGFR inhibitors

Author for correspondence:
Chiara Francavilla
e-mail: chiara.francavilla@manchester.ac.uk

Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer

Chiara Francavilla^{1,3} and Ciara S. O'Brien^{2,3}

¹Division of Molecular and Cellular Function, School of Biological Science, Faculty of Biology, Medicine and Health (FBMH), University of Manchester, Manchester M13 9PT, UK

²The Christie Hospital NHS Foundation Trust, Wilmslow Road, Manchester M20 2BX, UK

³The Manchester Breast Centre, University of Manchester, Wilmslow Road, Manchester M20 4GJ, UK

CF, 0000-0003-1775-3386

Fibroblast Growth Factor Receptor (FGFR) signalling plays a critical role in breast embryonal development, tissue homeostasis, tumorigenesis and metastasis. FGFR, its numerous FGF ligands and signalling partners are often dysregulated in breast cancer progression and are one of the causes of resistance to treatment in breast cancer. Furthermore, FGFR signalling on epithelial cells is affected by signals from the breast microenvironment, therefore increasing the possibility of breast developmental abnormalities or cancer progression. Increasing our understanding of the multi-layered roles of the complex family of FGFRs, their ligands FGFs and their regulatory partners may offer novel treatment strategies for breast cancer patients, as a single agent or rational co-target, which will be explored in depth in this review.

1. Introduction

Since the 1980s, there has been an explosion of novel molecular targets to guide drug development strategies for cancer treatment [1]. In breast cancer, this has translated to increased systemic therapeutic options, which, alongside refinements of the diagnostic pathway, have improved median survival (Cancer Research UK 2019, <https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk>). Sadly, despite these undoubted advances, breast cancer remains second only to lung cancer as the highest cause of female cancer-related mortality. There is an exigency for novel molecular-targeted therapies (MTTs) to improve patient survival outcomes in early and metastatic breast cancer.

Here, we will first explore how the complex Fibroblast Growth Factor Receptor (FGFR) family, its ligands and cofactors regulate fundamental cellular processes in breast cells and tissue. We will highlight the role of the FGFR axis in normal breast development and in signalling dysregulation in breast tumorigenesis and treatment resistance [2–4]. After discussing the case for anti-FGFR therapeutics as a rational target for drug development in breast cancer, we will outline clinical trial data on the use of FGFR-targeted therapies in cancer patients, to date. Finally, we will focus on future perspectives for FGFR-targeted therapy in breast cancer.

2. Overview of FGFR signalling

Receptor Tyrosine Kinases (RTKs) are single-pass transmembrane proteins, whose overexpression is associated with breast and other cancers and decreased disease-free survival [5,6]. Among these RTKs, there are epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), insulin-like growth factor receptors (IGFRs) and FGFRs [6] (figure 1*a*). Upon ligand




Figure 1. Schematic of the breast cancer epithelial cell and extracellular environment. (a) Breast cancer epithelial cells express different combinations of RTKs including EGFR, VEGFR, PDGFR, IGFR and FGFRs, all with a known role in breast cancer. Furthermore, breast cancer epithelial cells express either HER2, or progesterone/oestrogen receptors or none of these three receptors in HER2-positive, ER/PR-positive and triple negative breast cancers (TNBCs), respectively. (b) The breast cancer extracellular environment is composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature. Cells and proteins are not to scale.

stimulation, RTKs activate several pathways, including mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phospholipase C gamma ($PLC\gamma$) and phosphoinositide 3-kinase (PI3-K) [7] (figure 1a). RTK signalling regulates the response of cancer cells to perturbation of the extracellular environment, composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature [8] (figure 1b).

Here, we will focus on the complex family of FGFRs, their ligands FGFs and their signalling partners. The FGF/FGFR family comprises 18 proteins that bind to and activate four RTKs, FGFRs 1–4. The different subfamilies are based on the biochemical properties, sequence similarities and evolutionary relationships of their members (figure 2a,b). Proteins of the extracellular matrix, like Heparan Sulfate Proteoglycans (HSPGs), and cofactors, like the Klotho proteins, regulate the interaction between the FGFs and their receptors at the plasma membrane [4,9,10] (for more details, see §3).

Upon binding of FGF and specific cofactors, dimerization of the FGFR kinase domain induces the phosphorylation of

tyrosine (Y) residues leading to full receptor activation and phosphorylation and recruitment of adaptor proteins. Firstly, Y653, in the activation loop, is phosphorylated, followed by the phosphorylation of Y583, Y463, Y654, Y677, Y766 and Y585, whereas Y730 is weakly phosphorylated [11–13] (figure 2c). After autophosphorylation, FGFRs are coupled to intracellular signalling pathways, including the RAS-MAPK, PI3K-AKT, $PLC\gamma$ and STATs pathways [4,14]. FRS2 α , which is constitutively associated with the receptor, is phosphorylated upon ligand binding, and recruits adaptor proteins, like GRB2, which in turn recruits SOS followed by members of the MAPK family, and GAB1, which then activates the PI3K-AKT signalling axis [15] (figure 2c). PI3K can also be activated directly upon FGF10 binding of FGFR2b [11]. The MAPK pathway, including ERK1/2, JNK and p38 kinases [16–18], regulates transcription [19] and recruits negative signalling regulators like the E3 ligase CBL, the adaptor SPROUTY and the phosphatase SHP2 [20,21]. By contrast, AKT induces the activation of the mTOR complex 1 [22] and the phosphorylation of the FOXO1 transcription factor [23] (figure 2c). Following




Figure 2. The FGFR signalling players. (a) Table showing the FGF subfamilies. (b) Table showing the FGF/FGFR pair ligand specificity. FGF colour is based on (a). (c) Overview of the signalling pathways activated upon FGF binding to FGFR. The numbering in the cytoplasmic domain of FGFR refers to FGFR1c. HSPGs, heparan sulfate proteoglycans.

recruitment to activated FGFR the enzyme PLC γ induces calcium ion release, resulting in the activation of downstream kinases like PKC [24] (figure 2c). Finally, FGFR also activates STAT1, 3 and 5, which regulate gene expression in the nucleus [25] (figure 2c).

3. FGFs, FGFRs and cofactors

The FGF family includes secreted FGFs—the FGF1, FGF4, FGF7, FGF8, FGF9 and FGF15/19 subfamilies—and intracellular FGFs—the FGF11 subfamily [26,27] (figure 2a). Secreted FGFs are expressed ubiquitously and play crucial roles in early embryonic differentiation and development; during organogenesis of the heart, limb, lung, mammary gland, pancreas, liver, kidney, ear and brain; and in the homeostasis of adult tissues, where they are important for tissue maintenance, repair in wound healing, regeneration and metabolism [28–37]. Secreted FGFs can function as autocrine, paracrine or endocrine factors, and regulate all fundamental cellular processes, including proliferation, survival, migration and differentiation [4]. In addition to the canonical FGF functions, endocrine FGFs of the FGF15/19 subfamily also mediate phosphate, bile acid, carbohydrate and lipid

metabolism [38,39]. Whereas FGFs require HSPGs to fully activate their receptor, endocrine FGFs have reduced affinity for HSPGs and signal through the Klotho family [38]. The intracellular FGFs—also known as FGF homologous factors (FHF) (figure 2a)—serve as cofactors for members of the voltage-gated sodium channel family, mitogen-activated protein kinase 8-interacting protein 2 (MAPK8IP2), β -tubulin and NF- κ B essential modulator (NEMO) [40–43]. They function as essential regulators of neuronal and myocardial excitability, but their role during embryonic development and human diseases is less clear [44].

The FGF receptors (FGFRs) contain about 800 amino acids in several domains, including three extracellular immunoglobulin-like domains (I, II and III), a transmembrane domain and two intracellular tyrosine kinase domains. There are five *FGFR* genes, and *FGFR1–3* can be alternatively spliced into variants of immunoglobulin-like domain III, referred to as 'b' and 'c', which are essential for ligand-binding specificity and are mainly expressed in epithelial and mesenchymal cells, respectively [4,45–47] (figure 2b). *FGFRL1/FGFR5*, which is a membrane protein of about 500 amino acids with three extracellular immunoglobulin-like domains (I, II and III), a transmembrane domain and a short intracellular tail with no tyrosine kinase domain [48], will be not considered

further. All FGFR isoforms can be activated upon FGF1 binding, although FGF1 has different affinities for each FGFR isoform [26,27]. FGFR1c and 3c interact with FGF2, members of the FGF4, 8 and 9 subfamilies, and with the endocrine FGFs (figure 2b). FGFR2c can bind the same FGFs as the other two mesenchymal isoforms of FGFR with the exception of the endocrine FGFs FGF21 and FGF23 [4] (figure 2b). The epithelial isoforms of FGFR1 and 2, FGFR1b and 2b, are preferentially activated by the FGF7 subfamily—with FGF7 specific for FGFR2b, whereas FGFR3b interacts with the FGF8 and 9 subfamilies [49,50] (figure 2b). The endocrine FGF15/19 subfamily has higher affinity for the mesenchymal isoforms of FGFR1–3 [4] (figure 2b). Finally, FGFR4 is activated not only upon FGF2, 4, 6, 8, 17 and 18 binding but also by the endocrine ligands FGF15/19 and FGF23 [51] (figure 2b). It is not known whether each FGFR isoform regulates specific downstream signalling outputs, although some evidence exists that FGFR1 signalling is similar to FGFR2 signalling but differs from FGFR3–4 signalling [4]. However, this variety of FGF/FGFR pairs influences cellular signalling architecture and downstream responses in all cells and tissue. For instance, mesenchymal tissues expressing FGFR1-2c are often activated by FGF ligands that are expressed in the surrounding epithelial cells, such as members of the FGF4 and FGF8 subfamilies, whereas epithelial tissues express FGFR1-2b and bind ligands secreted from mesenchymal tissues (e.g. FGF7 subfamily) [4] (figures 1 and 2b). This paracrine expression of ligands and receptors is crucial during FGFR-mediated development of branching organs, like the mammary gland [31], and has been found dysregulated in human cancers [2,10].

HSPGs, α -Klotho and β -Klotho are potent cofactors for FGFR signalling activation [52,53]. Heparan sulfate consists of chains of repeating sulfated disaccharides linked to *N*-acetylglucosamine; these chains are covalently linked to syndecan, perlecan and other transmembrane or cell surface-anchored core proteins, or diffusible proteins of the extracellular matrix [54]. HSPGs enhance the activity of FGFs by regulating the binding, stability, specificity and affinity of FGF/FGFR pairs, and sequester the FGFs by limiting the diffusion of secreted FGFs through the extracellular matrix [53]. This is crucial during development, as differences in binding affinity of FGF7 and FGF10 for HSPGs generate a gradient of FGFs which regulate epithelial branching during organogenesis [55,56]. The endocrine FGFs with reduced affinity for HSPGs require the single-pass transmembrane proteins α -Klotho and β -Klotho for receptor binding [52]. α -Klotho, which is expressed in the kidney and in the brain, was identified as a cofactor for FGF23 signalling through FGFR1c, FGFR3c and FGFR4 to regulate phosphate and calcium homeostasis [57]. β -Klotho is mainly expressed in the liver and white adipose tissue and is required by FGF15/19 and FGF21 to activate FGFR4 and FGFR1c, respectively [58]. The Klotho cofactors can also directly compete with the FGF8 subfamily members for the binding of their receptors, thus inhibiting their actions while activating endocrine FGFs [59].

Genetic alterations of the *FGF*, *FGFR* or *cofactor* genes—like mutations, Single Nucleotide Polymorphisms (SNPs) or amplifications—have been shown to affect cellular responses during development, in genetic diseases and cancer, including breast cancer [3,60,61]. This is demonstrated by the variety of phenotypes observed in *Fgf*, *Fgfr*, *Hspg* and *Klotho*

knock-out mice (summarized in [4]), reflecting the fundamental roles that FGFR signalling has in several pathological conditions. For instance, mice not expressing *Fgfr2b* or its ligand *Fgf10* present impaired signalling underlying the formation of branching organs, including lungs, kidney or mammary gland (see §4.2) and die at birth (P0). Therefore, FGFRs, FGFs, signalling cofactors and partners require robust and specific regulatory mechanisms to guarantee the activation of the right output in the right condition in both physiological and pathological conditions.

4. FGFR signalling in health and disease

4.1. FGFR signalling regulation in tissue homeostasis

Aberrant activation of FGFR signalling in cells and organs is associated with development defects, genetic and metabolic disorders, and cancer. Therefore, FGFR signalling needs to be tightly regulated. Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3). The presence and the amount of different FGFs in the extracellular matrix affect downstream signalling architecture. For instance, FGF7 and FGF10, which activate FGFR2b [62], induce transient and sustained ERK1/2 phosphorylation in epithelial cells, which results in opposite long-term outputs, proliferation and migration, respectively [11]. The concentration of these two members of the FGF7 subfamily in the extracellular environment triggers also specific branching patterns during organogenesis [56]. Thus, the different affinity of FGF7 and FGF10 for HSPGs is a key regulatory mechanism underlying the response to these FGFs in epithelial cells [55]. Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules *N*-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3). We have recently shown that EGFR regulates FGFR2b trafficking and signalling outputs in response to FGF10 stimulation [68]. In addition to FGFRs, FGFs and the cofactors HSPGs or Klotho proteins, the transcript and protein levels of these cell surface molecules change during development and in pathological conditions, thus fine-tuning FGFR signalling activation [10].

Differences in FGF-induced dimerization of FGFRs on the cell surface result in specific phosphorylation patterns on the receptor and in the recruitment of distinct signalling partners, thus determining the amplitude and dynamics of cellular responses [69]. This would explain how the formation of a stable FGF10/FGFR2b complex results in the phosphorylation of Y734 on FGFR2b, activation of ERK1/2 in a sustained manner, and regulation of cell migration [11]. By contrast, FGF7, which has less affinity for FGFR2b and for HSPGs compared with FGF10 [26,27,55], is not able to induce Y734 phosphorylation, thus leading to transient ERK1/2 phosphorylation and cell proliferation upon FGFR2b binding [11,69]. Similarities and differences in signalling of the four FGFRs could be also determined by subcellular localization (figure 3). For instance, the four FGFRs follow a different route after FGF1-induced internalization,




Figure 3. Mechanisms of regulation of FGFR signalling. Schematic of the main regulatory mechanisms of FGFR signalling, including ligand concentration and availability in the extracellular environment, the presence of co-partners on the plasma membrane, signalling inhibitors and signal localization.

as FGFR4 is recycled to the cell surface, whereas FGFR1–3 are degraded into lysosomes [70]. FGFR2b has been shown to be sorted into the degradative route upon FGF7 binding, and into recycling endosomes in response to FGF10 [11,71]. This different FGFR trafficking results in the activation of specific downstream signalling pathways [11,63,72]. Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).

Inhibitory mechanisms of signalling are also important for the precise regulation of FGFR functions in physiological and pathological conditions. For instance, GRB2 direct interaction with FGFR2c does not enable the recruitment of signalling adaptors to the C-terminus of the receptor, thus resulting in signalling attenuation [75]. The MAPK pathway can also exert negative feedback inhibition of FGFR signalling by directly phosphorylating the C-terminus of FGFR2 at serine 777 [76]. This is also an example of how other RTKs can regulate the activity of FGFRs by using members of the MAPK family. The ubiquitously expressed family of SPROUTY is a known negative regulator of RTK signalling. SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3). Phosphatases like DUSP6 or SHP2 attenuate the FGFR/MAPK signalling axis during development, and their deregulation may lead to cancer formation [79,80]. Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).

The combination of all these regulatory mechanisms plays a crucial role in modulating the nature, specificity, dynamics and amplitude of FGFR signalling outputs during homeostasis.

4.2. FGFR signalling in mammary gland development

FGFR signalling plays a crucial role in mammary gland formation during development. Mammary gland formation in the mouse begins around embryonic day 10 (E10) [2,82]. FGFR2b signalling is required for placode induction and development, as shown by the disappearance of mammary placode in *Fgfr2b* knock-out mice due to decreased proliferation of the epithelium [31]. However, in *Fgf10* knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2*a,b*). The expression of FGFR2b remains elevated in virgin mice but decreases during pregnancy and lactation. Indeed, the postnatal phase of mammary gland development is characterized by high ramification of the gland, which is mainly due to the FGF10/FGFR2b signalling, with FGF7 playing a minor role [31].

A crosstalk between FGF10 and WNT signalling has been described during mammary placode development [31,83], where FGF10 controls the expression of the *Wnt* ligands, including *Wnt10b* [84]. It has been suggested that FGF10 and WNT signalling are both required for regulating cell migration during mammary placode induction [84]. FGF10/FGFR2b signalling is also important for branching of the mammary epithelial tree, which starts at E15.5 but occurs mostly postnatally [85]. Indeed, the mammary gland epithelium fails to ramify in the *Fgf10* knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2*a,b*). During the 2 month period following birth, the mouse mammary gland is subjected to extensive branching through cell proliferation and differentiation events of the terminal end buds (TEBs) of the mammary ducts [2]. The formation of TEBs depends on ER signalling, which probably controls FGFR2b signalling [2]. The TEBs contain mammary

progenitors giving rise to both luminal epithelial and myoepithelial cells, and the continuous interaction of TEBs with the surrounding microenvironment is crucial for the maintenance of the lumen structure and for milk secretion [2]. This interaction is lost during early-stage breast cancer and is controlled by paracrine signalling including FGF10/FGFR2b signalling and FGF20 signalling [85,87].

Interestingly, whereas deletion of the *Fgfr1* gene in the mammary epithelium has minor effect on the development of the mammary gland, the simultaneous depletion of *Fgfr1* and *Fgfr2* genes leads to a significant loss of stem cell progenitors and defective epithelial branching [88]. Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2*a,b*). The role of these FGFs in the stroma has been recently elucidated [89]. FGF2 and FGF9 regulate sustained signalling activation of primary fibroblasts from mammary gland, and FGF2 could induce fibroblast proliferation, migration and remodelling of the extracellular environment [89]. Altogether, these data define a crucial role for FGFR signalling in the development of mammary gland both pre- and postnatally and suggest a role also in remodelling of the extracellular environment and in the formation of early lesions during breast cancer.

4.3. FGFR signalling in breast cancer

Dysregulation of FGFRs, FGFs and downstream signalling molecules has been described in breast cancer [2,89]. The term breast cancer encompasses a heterogeneous group of invasive cancers, whose cell of origin derives from primary breast tissue and where biological aggressiveness is indicated by tumour grade and proliferation rate [90]. Commonly, breast cancers will arise within cells (or their developmental progenitors) lining the ducts or composing the lobules of the glandular breast. This ductal/lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1*b*). Breast cancer may be defined into three broad clinical subtypes ((hormone receptor (ER/PR)-positive (approx. 70%), HER2-positive (approx. 20%) and triple negative breast cancer (TNBC, approx. 10%)), using laboratory-based immunohistochemistry and/or *in situ* hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1*a*). To date, these broad clinical subtypes have been the tenets of therapeutic decision-making. On a genomic level, at least four intrinsic molecular breast cancer subtypes can be defined in breast cancer tissue, including luminal A, luminal B, HER2-positive and basal-like breast cancers [91]. Intrinsic molecular subtype, as defined, for example, by PAM-50 classification [92], may be used as a risk predictor for adverse clinical outcomes [93]. Current clinical trial strategies may combine clinical and molecular subtypes to guide treatment personalization and validate clinical decision-making (e.g. [94,95]), and/or pre-select (pre-screen) patient population for predictive biomarkers indicative of treatment sensitivity [96].

The bioinformatic analysis of available data from BioPortal (<http://www.bioportal.no/>) suggests that *FGFR1* gene alterations are as significant in breast cancer patients as alterations in other known drivers of breast cancer (e.g. HER2) [97]. Furthermore, several studies have shown that FGFR signalling is important for the growth of breast cancer cells *in vitro*

[98–102]. Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4). Mutations cause constitutive activation of FGFR signalling, whereas changes in FGFR isoforms increase the FGF/FGFR pairs capable of inducing cell growth [3]. The first studies on the role of FGFR in breast cancer identified the amplification of *FGFR1* and *FGFR2* genes in human breast cancer samples [103]. Since then, genome-wide association studies [104] have associated SNPs within the *FGFR2* gene with increased breast cancer susceptibility [105]. Very recently, genetic alterations of FGFRs have been associated with breast cancer metastases and included in the list of actionable targets in breast cancer [106–108]. In metastatic breast cancers, FGFRs are for instance implicated in poor response to chemotherapy [109] and resistance to targeted therapies [110]. FGFR dysregulation may also play a role in organ-specific metastases in breast cancer. In a recent study, FGFR1 and p53 mutation was associated with central nervous system (CNS) metastases in a breast cancer patient cohort [108] and *FGFR2* amplification was reported as a clonal event in CNS metastases in a warm autopsy series [111]. FGFR4-induced genomic signature was also found to be predictive of organ-specific metastases (brain, liver, lung) in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) breast cancer patient cohort independent of clinical subtype or stage [112].

Numerous *FGF* genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4). Furthermore, FGFs can act synergistically with VEGF to amplify tumour angiogenesis [114]. The tumour microenvironment consists of cancer cells, adipocytes and stromal/immune cells, such as fibroblasts, endothelial cells, lymphocytes and macrophages, and is involved in cancer cell proliferation, invasion and metastasis [115] (figures 1 and 4). FGFs deriving from cancer cells or stromal cells and their receptors on cells of the breast tumour microenvironment are key players for the regulation of tumour cell remodelling [116,117], immune surveillance and evasion [118], and response to therapies [119]. Resistance to anti-cancer therapies has been attributed not only to overexpression of FGFs, but also to increased abundance of FGFR and members of the FGF/FGFR signalling axis, like MAPK [120,121].

We present below an overview of the known roles of the FGF subfamilies and of FGFR1–4 in breast cancer progression and metastasis. We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).

5. FGFs in breast cancer

5.1. The canonical FGFs

5.1.1. The FGF1 subfamily: FGF1, FGF2

The FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF)




Figure 4. Roles of the FGFR family in breast cancer. Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2). The asterisks indicate the three main FGFR isoforms with a critical role in breast cancer progression. The text in burgundy indicates the mechanisms underlying FGFR roles in breast cancer, including secretion of FGFs, interactions with proteins of the extracellular matrix, regulation of vasculature during angiogenesis, crosstalk with HER2, regulation of signalling, metabolism and transcription, changes in intracellular localization, and genomic alterations, as described in the main text. The black lines on the 'FGF' text indicate the lack of available information on the role of those specific FGFs in breast cancer.

(figure 2*a,b*), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4]. Both FGF1 and 2 are present in the breast, with FGF2 localized to myoepithelial cells of normal breast, and signal through FGFR1, 2 and 4 [122] and HSPGs [123]. Very recent data suggest that the stabilization of FGF2 changes the nature and the dynamics of FGFR signalling in primary mammary fibroblasts, suggesting a crucial role for the FGF2 interaction with extracellular matrix proteins, like HSPGs, in dictating breast cancer signalling [124]. FGF2 regulates tumour growth and migration *in vitro* and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4). The overexpression of its high molecular weight isoform induces lung metastasis and confers endocrine resistance in pre-clinical models [128]. Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4). It would be interesting to block either FGF or both using available single-chain variable fragment (scFv) antibodies and their dimerization form, which have been shown to inhibit FGF1-dependent breast cancer growth *in vitro* [131,132]. This strategy is based on the idea of inhibiting FGF signalling with

ligand-trap molecules or antibodies and not the receptor or downstream signalling players [133].

5.1.2. The FGF4 subfamily: FGF4, FGF5, FGF6

The FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2*a,b*). In the context of breast cancer, the expression of FGF5 and FGF6 was detected at very low level in comparison with FGF1 and FGF2 [134]. By contrast, the FGF4 gene is amplified in breast cancer together with FGF3 and FGF15/19 as they are all part of the locus on human chromosome 11q13 that is frequently amplified in several tumours [135]. To the best of our knowledge, FGF6 signalling has not been associated with any phenotype in breast cancer neither *in vitro* nor *in vivo*, whereas FGF4 and FGF5 seem to have overlapping but also specific roles. Both FGF4 and FGF5 regulate resistance to HER2 inhibitors. FGF4 promotes resistance to lapatinib in HER2-positive breast cancer cell lines through FGFR1 signalling [136], and FGF5 by inducing FGFR2 activation, which in turn transactivates HER2 and promotes

resistance [137]. It would be worth investigating whether FGF4 and FGF5 act synergistically to promote resistance mechanisms or whether their role depends on other clinical parameters. FGF4 signalling regulates breast cancer cell migration and invasion [138–140], whereas FGF5 seems to have a specific role in the formation of bone metastasis as shown by its overexpression in metastatic samples compared with normal breast [141]. However, it has also been reported that low expression of FGF5 correlates with a protective role in breast cancer patients [142]. These contrasting results need further studies to uncover the mechanisms underlying FGF5 signalling in breast cancer.

5.1.3. The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22

Members of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2*a,b*), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2). The *FGF3* gene is amplified in breast cancer [135] and this correlates with a lower response in patients with HER2-positive breast cancer treated with anti-HER2 therapy [136]. FGF3 levels correlate with stage and grade, FGFR2 signalling activation and proliferation of breast cancer cells [143]. Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4). FGF7 and FGF10 are among the components of breast cancer organoid growth medium [144], indicating that they both play a crucial role in the initiation and/or maintenance of breast cancer. FGF7 is detected in both stroma and tumour cells [145] and increases breast cancer cell proliferation and migration *in vitro* [146–148]. Interestingly, AKT signalling is required for such FGF7-mediated regulation of tumour progression [148,149]. In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2*b*) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150]. Furthermore, FGF7/FGFR2 signalling induces the downregulation of progesterone receptor (PR) via the kinase RSK2, which correlates with poor prognosis in the clinic [151]. Finally, the FGF7/FGFR2 signalling axis increases ER phosphorylation, ubiquitination and subsequent ER proteasomal degradation, which results in resistance to tamoxifen treatment [152]. Altogether, these data show that FGF7 signalling through FGFR2b is crucial for promoting breast cancer through different mechanisms and drives resistance to conventional therapies.

FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4). FGF10 expression increases if the rs10941679 SNP is present, which in turn would increase risk of breast cancer in patients expressing the *FGFR2* SNP rs2981578 variant [155,156]. This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2*a,b*). FGF10 regulates Epithelial to Mesenchymal Transition (EMT), cell viability, migration and colony formation in breast cancer cell lines by increasing the expression of mesenchymal factors (such as vimentin, *N*-cadherin, snail, slug, TGF- β), and ERK1/2 and PI3K–AKT signalling [2,158]. FGF10 stimulation of the ER-positive breast cancer cell line MCF-7 decreases dependency on oestrogen and sensitivity to treatment with

anti-oestrogen [159], suggesting that anti-FGF10/FGFR inhibitors can be used to bypass resistance to anti-hormone therapies.

In conclusion, the FGF7 family—except for FGF22 whose role in breast cancer has not been reported yet—plays a crucial role not only in the formation of mammary gland during development, but also in breast cancer initiation, progression and resistance to therapies.

5.1.4. The FGF8 subfamily: FGF8, FGF17, FGF18

The FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2*a,b*). FGF8 is crucial for early-stage development, FGF17 controls development of the brain, and FGF18 is essential for multiorgan development as *Fgf18* knock-out mice die at birth similar to the *Fgf10* knock-out mice [4]. FGF8 expression is higher in malignant breast tissue compared with normal cells [160]. As the canonical FGF8 receptors FGFR2c and FGFR3c are expressed at low level in breast cancer cells, it is possible that FGF8 acts in an autocrine manner on FGFR1 and FGFR4, which are instead present in the breast epithelium [160] (figures 2*b* and 4). It has been reported that one of the FGF8 isoforms, FGF8b, increases anchorage-independent growth *in vitro* and vascularization in nude mice [161,162], suggesting that FGF8 is involved in the induction of transformation and in angiogenesis in breast cancer. Given the role of FGF8b in regulating the differentiation of osteoblasts, a potential role of FGF8b may include driving the formation of osteosclerotic bone metastases [163]. FGF8 signalling increases oestrogen-induced breast cancer cell proliferation by inducing the expression of the ER mRNA, and at the same time suppresses the inhibition of mitosis by activating the cell cycle regulator CDC2 and other regulators of cell cycle entry [164,165]. The increased expression of FGF18 mRNA and protein has been associated with migration *in vitro* and poor overall survival in cancer patients [166]. A recent study showed that FGF18 increased cell migration and EMT through AKT signalling and by inducing the transcription of proliferation-related genes, including *CDC2*, metastasis-related genes (*TGF β* , *MMP-2* and *MMP-9*) and EMT markers like the SNAIL proteins and *N*-cadherin [167]. Both FGF8 and FGF18 have a role in regulating the cell cycle of breast cancer cells, a finding that deserves further investigation in the search for novel potential treatments for patients with highly proliferative breast cancer.

5.1.5. The FGF9 subfamily: FGF9, FGF16, FGF20

Members of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2*a,b*)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4]. FGF16 and FGF20 do not have a known role in breast cancer progression. On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4). FGF9 is capable of inducing cancer stem-like cell properties in breast cancer cell lines and freshly isolated breast cancer cells through FGFR activation [168]. Furthermore, a recent publication suggested a role for FGF9 in resistance to the commonly used anti-cancer agent gemcitabine [169].

5.2. The endocrine FGFs: FGF15/19, FGF21, FGF23

The endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2*a,b*). *Fgf15* knock-out mice present defects in cardiac development and deficiency in the intestine functions through cell cycle regulation; *Fgf21* depletion does not affect development but profoundly impairs metabolism in fasting conditions; and *Fgf23* knock-out mice die at birth owing to increased levels of vitamin D, hyperphosphataemia and cardiac defects [4]. The human *FGF19* gene is amplified in breast cancer together with *FGF3* and *FGF4* [135], and this correlates with worse prognosis in invasive ductal breast carcinomas, particularly in older patients with lymph node metastasis and negative ER status [170]. Genetic knock-out of *FGF19* decreases breast tumour progression and metastasis in either mouse models of breast cancer or experimental metastasis models [171]. The authors of this discovery demonstrated that FGF19 activates the AKT signalling pathway through FGFR4, and that this is critical for the oncogenic role of FGF19 [171]. Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).

5.3. The intracellular FGFs: FGF11, FGF12, FGF13, FGF14

Mice knocked-out for intracellular FGFs (figure 2*a,b*) present various defects in neurons (*Fgf13* and *Fgf14* knock-out) and altered voltage-gated sodium channel physiology (*Fgf14* knock-out) [4]. FGF13 and FGF14 might be tumour suppressors in breast cancer. Indeed, a long non-coding RNA, FGF13-AS1, inhibits breast cancer cell proliferation, migration and invasion by reducing the half-life of Myc, and of insulin-like growth factor 2 mRNA binding proteins (IGF2BPs) [174]. On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4). By contrast, other studies show that FGF13 may promote metastasis by altering breast cancer cell migration, especially in TNBC [176,177]. Further analyses of patient-derived samples and experiments are needed to clarify these results.

6. FGFRs in breast cancer

6.1. FGFR1

The *FGFR1* gene on the 8p11–12 chromosomal region is mutated in around 15% of breast cancer, more specifically in 27% of HER2-positive patients, in 23% of ER-positive patients and in 7% of TNBC patients [3,104,178]. This chromosomal region is amplified simultaneously with the 11q12–14 region, which contains other oncogenes with a role in breast cancer progression, like *CCND1*, *FGF3*, *FGF4* and *FGF19* [135]. However, the fact that translocations and mutations of the *FGFR1* gene lead to a constitutively activated FGFR1 protein in around 10% of tumours [179–181] highlights the unique role of FGFR1 as an oncogene and its accountability during the arise of resistance. Indeed, besides

correlating with low survival rates in lobular and metastatic breast cancer [109,182], *FGFR1* gene amplification is implied in resistance to hormone therapies [183], to anti-HER2 treatments [136] and to CDK4/6 inhibitors [184]. *In vivo*, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4). *FGFR1* gene fusions, which account only for 8% of the total gene aberrations, have been observed with *Fop*, *Bcr* and *Znf198* [104]. Despite the rarity of kinase fusion events in breast cancer, these events showed an enrichment in hormone-resistant samples and in metastasis [185].

FGFR1 signalling has been shown to be amplified by activating mutations like K656E and N546 *in vitro* and in malignant breast cancer compared with normal breast [13,186]. In the *FGFR1*-amplified cell line MDA-MB-134, treatment with an anti-FGFR1 antibody reduced the phosphorylation of FRS2 and ERK1/2 downstream of the receptor, which resulted in the reduction of tumour growth in pre-clinical models [179]. High levels of FGFR1 are known to induce MAPK activation and subsequent expression of cyclin D, leading to increased cell cycle progression and cell growth [183]. These examples illustrate the transforming ability of FGFR1 signalling in breast cancer cells and point to the FGFR1/MAPK signalling axis as a prominent drug target. Besides regulating cell proliferation, the FGFR1-dependent activation of ERK1/2 is implicated in epithelial to mesenchymal transition (EMT) by stabilizing the transcription factor Twist in HER2-positive breast cancers [187]. This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).

FGFR1 regulates EMT also through integrin $\beta 3$ signalling, which disrupts the known interaction between FGFR1 and E-cadherin on epithelial cells and leads to redistribution of FGFR1 in sub-cellular compartments [188]. This cellular mechanism favours three-dimensional outgrowth of metastatic breast cancer cells in the presence of FGF2 *in vitro* and correlates with decreased survival in patients with basal-like breast cancer [188]. On the contrary, the AKT–mTOR signalling pathways are involved in FGFR1-dependent regulation of anoikis and autophagy, thus contributing to the tumorigenic activity of FGFR1 [189]. In addition to AKT and ERK1/2 activation, FGFR1 induces the activation of the IGF1R pathway through the recruitment of IRS1 in breast cancer cells resistant to the inhibitor metformin, thus suggesting a connection between growth factor mitogenic signalling and glucose metabolism in breast cancer cells [190] (figures 1 and 4). FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4). Breast cancer cell behaviour can also be regulated *in vitro* by nuclear translocation of FGFR1b upon FGF10 binding, and this change in sub-cellular localization of FGFR1b regulates transcription and correlates with breast cancer invasion in clinical material and a three-dimensional model of breast cancer [73]. Therefore, the fine regulation of FGFR1 localization-dependent signalling may be a crucial factor contributing to the aggressiveness of breast cancer.

FGFR1 signalling may promote perturbations of the breast cancer microenvironment and immune response

which might lead to the formation of metastasis. For instance, FGFR1 is implicated in macrophage-dependent cell migration and invasion by activating the TGF β /SMAD signalling axis and the receptor for inflammatory cytokines Cxcr2 [192]. These results indicate that macrophages may be important for promoting FGFR1-driven breast cancer metastasis. FGFRs activating FGFR1 have the capacity to increase the differentiation of osteoclast; therefore it has been suggested that this would increase FGFR1-dependent migration of breast cancer cells towards the bones, one of the known metastatic sites in breast cancer patients [193]. More recent data have shown that the role of FGFR1 in distant metastasis is to amplify the effect of HER2 overexpression, and this would correlate with a less favourable prognosis in patients co-amplifying both *FGFR1* and *HER2* (8%) compared with patients with either *FGFR1* or *HER2* amplification or without amplification [194]. This idea was confirmed by data showing that FGFR1 amplification was strongly associated with increased risk for distant disease in axillary node-, HR- and HER2-positive early breast cancer [195]. It is interesting to note that there is a difference in the capacity of FGFR1 isoforms to promote an aggressive phenotype, with the FGFR1 β isoform inducing higher motility than FGFR1 α [196]. The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).

6.2. FGFR2

The *FGFR2* gene is located on the 10q26.13 chromosomal region, which is amplified in only 5% of all breast cancer patients, in particular TNBC patients [199]. In TNBC, *FGFR2* amplification has been associated with robust activation of signalling, cellular transformation and resistance to FGFR inhibitors in pre-clinical models [3,22,103,200]. However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4). There are 12 known mutations in the *FGFR2* gene reported in the COSMIC database (<https://cancer.sanger.ac.uk/cosmic>), among which four missense mutations are capable of constitutively activating FGFR2 (N549K, S253R, K660N and P253R) [104,202] and two (M538I and N550 K) contribute to FGFR2-dependent resistance to CDK4/6 inhibitors in ER-positive breast cancers [110,184]. Thus, the position of these mutations on the protein affects the function of FGFR2 in breast cancer, suggesting that multiple regulatory mechanisms for FGFR2 signalling are present *in vivo*. Genome-Wide-Association-Studies (GWAS) have shown that SNPs in the second intron of the *FGFR2* gene are significantly associated with high risk of breast cancer, in particular in post-menopausal women [105,203–205], confirming an oncogenic role for *FGFR2*. *FGFR2* maintains a population of tumour-initiating cells in mice, and claims have been made that FGFR2 can be targeted to eliminate breast cancer stem cells [206]. From a mechanistic point of view, it has been suggested that histone acetylation modulates access to selected polymorphic sites within intron 2, thus regulating downstream splicing sites, which generates FGFR2c isoforms [207]. As there is also evidence for gene

polymorphism of the FGFR2b ligand FGF10 [208], it would be worth exploring in detail the consequences of these nuclear events on the expression of different receptor isoforms and on signalling activation and specificity in both pre-clinical models and patient-derived samples. Interestingly, BRCA-1- and ER-double-positive breast cancers showed not only increased expression of FGFR2 [209] but also the presence of the SNP rs2981582 [210], which is associated with high risk of breast cancer [211]. Therefore, these data suggest that different *FGFR2* SNPs or their combination may contribute to initiation, signalling or elevated risk of breast cancer, highlighting the importance of the analysis of *FGFR2* SNPs as clinical markers or predictors.

Given the complex regulation of the *FGFR2* gene it is not surprising that FGFR2-dependent signalling is deregulated in breast cancer [211]. For instance, the amplification of *FGFR2* results in the activation of PI3K–AKT signalling and inhibition of apoptosis in breast cancer cell lines [199]. Furthermore, FGFR2 activates ERK1/2, which results in inhibition of transcription through the double-strand break repair protein Mre11A [212]. FGFR2 phosphorylation and ERK1/2 activation are reduced in NOD/SCID mouse models xenografted with breast cancer tumours overexpressing FGFR2 followed by treatment with the FGFR2 inhibitor dovitinib (TKI258) [206]. This amplification of FGFR2-dependent signalling might be due to splicing variants of *FGFR2* [213]. For instance, the shorter FGFR2-C3, expressing a short cytoplasmic tail, induces cellular transformation in human mammary epithelial cells because FRS2 is constitutively phosphorylated, even in the absence of any ligand, and robustly activates downstream signalling [213]. Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4). A potential mechanism for this implies FGFR2-dependent increase in the binding of two transcription factors associated with high-risk breast cancer, NFIB and YBX1, to the ER in the nucleus [159]. Like FGFR1, it is possible that FGFR2 localization in the cytoplasm or nucleus may affect downstream responses (e.g. ER signalling) and clinical parameters [214]. For instance, FGFR2 activation in mammary epithelial cells promotes the activation of the ribosomal s6 kinase 2 (RSK2) downstream from ERK1/2, which results in regulation of FGFR2 intracellular trafficking and increased cell growth and migration [215]. This signalling pathway has been identified in patient material as well, where the lack of FGFR2 and of activated RSK2 significantly correlated with better disease-free survival [215].

FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4). Therefore, FGFR2 may contribute to resistance to HER2 inhibitors. Indeed, FGFR2 inhibitors added to HER2-positive breast cancer cells after failure of treatment with the anti-HER2 drug lapatinib suggest a switch in cell addition to signalling inhibitors [101,217]. Recent data reported that FGFR2 is capable of phosphorylating HER2, leading to resistance both *in vitro* and *in vivo* [137]. Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4). This idea is in line

with novel clinical strategies to treat breast cancer patients with multiple signalling inhibitors, including FGFR1–2 [184,217]. An idea that is worth exploring would be the combination of FGFR2 and EGFR inhibitors, based on the reciprocal regulation of these two RTKs in breast cancer cells *in vitro* [68].

Finally, increased FGFR2 signalling possibly due to the SNP rs2981578 has been studied in stromal fibroblasts responding to FGF10 [155]. On the contrary, FGF7, another specific ligand for FGFR2b (figure 2*a,b*) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151]. In conclusion, FGF7 and FGF10 in the breast cancer microenvironment might regulate FGFR2 signalling-dependent breast cancer cell behaviour through complementary molecular mechanisms. This idea might lead to better therapies if confirmed in patient samples.

6.3. FGFR3

FGFR3 is located on chromosome 4p16.3 and is found mutated in a very low percentage of breast cancer patients, in particular in the extracellular (R248C, S249C) or the transmembrane (G370C, S371C, Y373C, G380R, A391E) protein domains, and more rarely within the kinase domain (K650E, K650N, K650M, K650T, K650Q and N540S) [104]. Gene fusions with *AFF3*, *AHCYL1*, *BAIAP2 L*, *1SLC45A3*, *BICC1*, *PPAPDC1A*, *TACCL1*, *TACC2*, *TACC3*, *NPM1* have also been reported, but not fully characterized [104]. However, there is recent evidence showing that the *FGFR3*–*TACC3* gene fusion is highly expressed in TNBC cell lines, which results in the autophosphorylation of FGFR3 [218]. Although *FGFR3* gene expression and FGFR3 are rarely found in breast cancer patients, these data suggest a potential oncogenic role for FGFR3. Amplification of the *FGFR3* gene has been found in less than 1% of breast cancer patients [104]. However, FGFR3 expression is associated with ER-positive breast cancers, where it contributes to tumour progression [219]. For instance, FGFR3 expression is increased in tamoxifen-resistant breast tumours and FGFR3 activation in MCF7 cells activates the MAPK, PI3K and PLC γ pathways [220], confirming its putative role in breast cancer development and resistance to endocrine therapy.

6.4. FGFR4

The *FGFR4* gene is located on the chromosomal region 5q35.2, and the FGFR4 protein has been found mutated at K535 and E550 in the kinase domain in breast cancer patients, which causes protein autophosphorylation and activation [104]. These mutations are mainly found in metastatic breast cancers [221], suggesting a positive correlation between FGFR4 signalling and metastatic breast cancer. On the same lines, the FGFR4-R388 allele has been associated with tumorigenesis, cell motility and immune evasion [222]. *FGFR4* gene amplification has been found in only 2.3% of breast cancer patients [104], but another study has revealed the presence of FGFR4 mRNA transcript in 30% of patients [134], particularly in metastasis [223]. The discrepancy between gene amplification and the level of transcript or protein can be explained by gene amplification not reflecting protein expression and activity in the case of FGFR4. For instance, high FGFR4 mRNA levels predict failure of

treatment with tamoxifen independently from the traditional predictive factors [224]. This would confirm that transcript and protein expression might be better predictors for treatments in breast cancer patients than gene amplification [225].

Few data are available on the association of the *FGFR4* gene or FGFR4 protein with specific breast cancer subtypes. Recently, two studies reported that FGFR4 acts as an important mediator of endocrine resistance and metastasis in invasive lobular carcinoma [221] and luminal A primary breast tumours (HER2-negative) that gives rise to HER2-enriched metastases [112]. Bioinformatics analysis further demonstrated that an FGFR4-induced gene signature predicts site-specific metastasis for lung, liver and brain, but not for bone or lymph nodes [112]. Certainly, FGFR4 cooperates with HER2 to regulate the expression of cyclin D and promote breast cancer cell proliferation [226]. FGFR4 is also a potential mediator of cell survival via activation of PI3 K–AKT signalling [227]. A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2*a,b*), which might increase AKT signalling. The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).

A potentially targetable function of FGFR4 is its tumour-delaying effect when metabolism is altered [228]. Although the primary role of FGFR4 in metabolism occurs in hepatocytes, its ablation results in a net inhibitory effect on mammary tumour progression, most likely due to suppressing signals triggered by FGF21 from breast adipocytes [228]. Systemic and microenvironmental metabolic alterations may indeed affect both peripheral and breast adipocytes, thus contributing to the suppression of tumour progression [228], but further studies are needed to confirm this hypothesis. Data showing that FGFR4 is overexpressed in invasive ductal carcinomas and that FGF15/19 signalling mediates the survival of a subset of basal-like breast cancer through FGFR4 and PI3K–AKT signalling confirm the link between metabolism alterations due to FGFR4 levels, survival and an aggressive breast cancer phenotype [227,229]. Furthermore, FGFR4 has been identified as a critical modulator of enhanced glucose metabolism in breast cancer cells, where high levels of FGFR4 not only increase glucose metabolism but also lead to chemoresistance [230]. Finally, the role of FGFR4 in resistance has been recently confirmed also in TNBCs [231], thus expanding the repertoire of breast tumours where FGFR4 signalling plays an important but still understudied role.

7. Targeting FGFR signalling in breast cancer

In breast cancer, the development of FGFR inhibitors represents a novel class of drugs. Theoretically, FGFR inhibitors might be positioned in three distinct clinical settings; as a ‘preventive therapy’ prior to a breast cancer diagnosis in high-risk patients, in the adjuvant setting to reduce risk of metastases after surgery for early breast cancer, or in the context of established metastatic breast cancer, to slow the natural history of the disease and thereby improve survival [105]. A GWAS of 1145 post-menopausal patients identified four separate SNPs in the FGFR2 intron associated with breast cancer susceptibility, and meta-

analyses of a large cohort of case control studies indicate that such FGFR2-susceptibility SNPs are present across ethnic groups and in different breast cancer sub-groups, predominantly hormone receptor-positive disease [232]. Based on FGFR2 interaction with other genetic and environmental factors (reviewed in [233]), FGFR2 may contribute to polygenic risk scoring in breast cancer family history clinics. However, this small contributory role to breast susceptibility is insufficient to support FGFR inhibitors as a candidate for drug prevention in high-risk women.

In the context of drug development of established breast cancer, proof of activity of a candidate protein in the metastatic setting must first be robustly observed. Three important aspects to consider from a clinical development perspective are: (1) Is the incidence of FGFR aberration in metastatic breast cancer clinically meaningful? (i.e. *Do you have the patient population to recruit to a clinical trial in a timely manner and is the patient population of sufficient size to render the drug commercially viable?*); (2) Can FGFR aberrations be promptly and accurately defined before study entry? (i.e. *Are FGFR aberrations easily identifiable in a time-sensitive manner before clinical deterioration from metastatic disease occurs? Can the right drug be offered to the right patient cohort?*); and (3) Is there a partner predictive biomarker to select for those patients who will derive most clinical benefit from FGFR inhibition? (i.e. *Are there clearly defined patient populations to aid commercial development?*). In the case of FGFRs, the presence of activating gene mutations in the FGFR axis, of various forms, has been reported in up to 18% of breast cancers, including *FGFR1* and *FGFR2* amplifications, point mutations in the ligand-binding region and oncogenic fusion proteins [104]. These data would corroborate the idea of FGFR as a clinically meaningful drug target. However, not all the *FGFR* gene aberrations can be easily identified in hospital laboratories by routinely used methods like immunohistochemistry or *in situ* hybridization on tumour biopsies but might require next-generation sequencing (NGS). At present, this level of precision oncology is not routinely available for most patients outside dedicated clinical trials. There is also a significant cost implication when scaled-up to real-world healthcare. The consequence of this potential delay in detecting *FGFR* aberrations is that during the time of the analysis the patient fitness for treatment may deteriorate owing to their burden of metastatic disease, thus making FGFR a difficult drug candidate. In spite of these clinical considerations, of particular interest to drug development is the observation that FGFR dysregulation is associated with the acquisition of endocrine resistance in hormone receptor-positive breast cancer, e.g. in the case of FGFR3 [112]. Multiple reports, including phase 2 clinical trial data, infer a role for the FGFR axis in resistance pathways to well-established metastatic treatment paradigms. For example, poor response to CDK4/6 inhibitors has been observed in patients with coexisting *FGFR1* amplification in hormone receptor-positive breast cancer [184] and dual HER2-targeted therapy in HER2-positive breast cancer [136]. Therefore, the FGFR signalling axis may be positioned as a single agent or in combination, to overcome resistance pathways to established therapies.

In terms of predictive biomarkers of disease response or resistance to FGFR pathway inhibition, FGFR dysregulation has been associated with PI3K, cyclin D1, MYC and p53 mutations in breast cancer [104]. Although it is unclear

whether these proteins are independent drivers or exhibit some degree of co-dependence, they may represent potential biomarkers or partner therapeutic opportunities with FGFR inhibitors, together with other potential dysregulated molecular drivers of breast cancer such as the RTK c-MET [234].

7.1. Clinical trials of FGFR inhibitors

In the past decade, several approaches have been used to target FGFR using non-selective and selective FGFR inhibitors across several cancer types, including breast cancer. Clinical trial data in breast cancer as a single agent or in combination are summarized in tables 1 and 2, respectively, with a particular focus on small molecule tyrosine kinase inhibitors.

7.1.1. Single-agent clinical trials

Proof-of-concept studies of FGFR pathway utility as a clinical target in solid tumours were initially performed using non-selective FGFR inhibitors in phase 1 studies. Examples of such non-selective agents include dovitinib (TKI258), which has activity against FGFR1–3, VEGFR1–3 and PDGFR, lucitanib, which has activity against FGFR1–2, VEGFR1 and colony stimulating factor receptor, and lenvatinib, with activity against FGFR1–4, KIT, RET and PDGFR beta [100,101,119,179,235,236]. Of course, multiple receptor targets can lead to multiple mechanisms of drug toxicity and therefore a move towards more selective FGFR drug development has been prioritized (table 1).

With increasing selectivity (and indeed sub-selectivity) for FGFRs, FGFR inhibitors have been assessed for dose, safety and tolerability within larger platform or basket trials to facilitate patient selection by NGS of tumour tissue or circulating tumour DNA. In NCI-MATCH [237], a platform trial in which drug selection was dictated by molecular profile rather than tumour histology, patients with cancers with targetable mutations in an FGFR pathway were treated with AZD4547, an orally bioavailable tyrosine kinase inhibitor, selective for FGFR1–3, until disease progression. Of the 70 patients assigned to AZD4547, 33% had metastatic breast cancer. The predominant FGFR aberration recorded was FGFR1 amplification or activating mutations in FGFR2 or 3. Response rates across the trial cohort were low (8%), consistent with the heavily pre-treated study population, and differed by mechanism of FGFR dysregulation. For example, patients with FGFR fusions showed the highest response rate of 22% to AZD4547 (90% CI 4.1–55%), with six-month progression-free survival (PFS) standing at 56%. In non-responders, there was a high prevalence of concurrent dysregulation of the PI3K/AKT/mTOR pathway. Tolerability of the drug was good, with most side effects concerning skin or mucus membranes and low grade in nature. The tumour-specific SAFIR-02 (NCT02299999) clinical trial is an open label phase 2 platform study that assigns drug treatment to metastatic breast cancer patients based on genomic profiling, compared with standard maintenance chemotherapy and/or immunotherapy. This study has recently closed to recruitment and results are anticipated soon. The study design includes AZD4547 for treatment of FGFR-dysregulated metastatic breast cancers, as assessed by high-throughput sequencing of frozen tumour tissue or circulating tumour DNA (ctDNA). In the FIGHT-207 multicentre phase 1 basket trial (NCT03822117), patients with solid cancers were

Table 1. Clinical trials of single-agent small molecule FGFR inhibitors in breast cancer. PFS, progression-free survival; CBR, clinical benefit rate; ORR, overall response rate; TEAE, treatment-emergent adverse events; DLT, dose-limiting toxicity; MTD, maximum tolerated dose; RP2D, recommended phase 2 dose.

trial identifier	phase	trial design	primary endpoint	current status
AZD4547				
NCT02299999 (SAFIR-02); start date November 2014	2	open label multicentre randomized trial, 1468 participants	PFS (compared with standard maintenance therapy)	active, not recruiting; estimated completion date December 2022
NCT02465060 (NCI-MATCH—breast protocol W); start date June 2015	2	open label multicentre trial, 70 participants	PFS (compared with standard maintenance therapy)	completed
INCB054828 (pemigatinib)				
NCT03822117 (FIGHT-207); start date January 2019	1	open label multicentre trial in patients with activating FGFR mutations or translocations, 170 participants, three cohorts— Cohort A: solid cancers with FGFR1–3 in-frame fusions; any FGFR2 rearrangement; FGFR1/3 rearrangement with known partner. Cohort B: solid cancer with activating mutations (excluding kinase domain) in FGFR1–3. Cohort C: solid cancers with FGFR1–3 known activating mutations in kinase domain; FGFR1–3 putatively activating mutations; other FGFR1/3 rearrangements	ORR	active, and recruiting; estimated completion date March 2022
BAY1163877 (rogaratinib)				
NCT04125693; start date October 2019	2	open label	TEAE	completed
RLY-4008				
NCT04526106; start date August 2020	1	open label first in human clinical trial in patients with solid cancers and activating FGFR2 mutation, FGFR2 fusion or FGFR2 amplification	MTD and RP2D	active and recruiting; estimated completion date October 2024
TAS-120 (futibatinib)				
NCT02052778; start date February 2014	1	open label dose escalation and expansion study and phase 2, 386 patients	ORR	active, not recruiting; estimated completion date June 2022

assigned to the treatment cohorts dependent on FGFR dysregulation type: Cohort A included FGFR–13 in-frame fusions, FGFR2 rearrangements or FGFR1/3 rearrangements with a specific partner; Cohort B included non-kinase domain activating FGFR13 mutations; and Cohort C, kinase domain activating mutations. All patient cohorts were given oral pemigatinib, an inhibitor of FGFR13 signalling transduction, which has recently been granted accelerated FDA approval for FGFR2-amplified cholangiocarcinoma [238]. The FIGHT-207 study has recently closed to recruitment and results are awaited. A further tumour agnostic basket trial, denoted FUZE (NCT03834220) is currently assessing objective

response rate to Debio-1347 in biliary, urothelial and solid cancers (including breast cancers) with FGFR1–3 fusions or rearrangements, based on encouraging phase 1 data. FGFR fusion screening is performed using whole-transcriptome sequencing, with a turnaround time of 14 days, a timeframe that is consistent with real-world clinical application. Planned recruitment is for 125 patients with interim futility/homogeneity analysis after 27 patients are on the study.

Rogartinib (BAY1163877) is a potent FGFR1–4 small molecule inhibitor that has recently completed dose-finding and safety assessment in the phase 1 trial setting [239] with activity predominately in urothelial, non-small lung cancers

and cholangiocarcinoma (time to progression 60–100 days), where FGFR overexpression was detected by mRNA expression. In the unselected solid tumour cohort (including breast cancers), median time on drug before progression was 47 days. Grade 3 toxicity was seen in fewer than 9% of patients (fatigue, anaemia, urinary tract infection). However, grade 1 or 2 hyperphosphataemia, anorexia or diarrhoea, which may still have meaningful detriment to quality of life in the metastatic setting, was seen in more than 33.3% of patients on the study [239]. Using a more traditional phase 1 clinical trial design, futibatinib, an orally bioavailable, irreversible inhibitor of FGFR1–4 demonstrated an overall response rate of 13% across several solid tumour types, including breast cancer [240]. Futibatinib is non-ATP-dependent and binds irreversibly to a cysteine loop in the receptor kinase region. Of the 170 patients assigned to this study, 50% had FGFR fusions or rearrangements, 30% had FGFR-activating mutations and 14% FGFR amplifications. Of the patients, 6.5% had a diagnosis of metastatic breast cancer with the majority having received between two and four prior lines of therapy. Responses to futibatinib were observed across the full spectrum of FGFR aberrations but were more commonly found in cholangiocarcinoma and primary central nervous system (CNS) cancers. Within the breast cohort, 3/11 patients showed some evidence of tumour shrinkage, with one FGFR2-amplified TNBC patient showing a prolonged partial response to futibatinib treatment, leading to further characterization of this drug in an ongoing phase 2 study (FOENIX, NCT04024436) in FGFR1- and FGFR2-amplified triple negative or hormone receptor-positive breast cancer.

In conclusion, there are several promising clinical trials based on single agents for which results are awaited that may change the way we treat patients with dysregulated FGFRs.

7.1.2. Combination-agent clinical trials

There has been increasing interest in developing novel partners to endocrine therapy, to overcome the inevitable progression to acquired endocrine resistance, after first-line single-agent aromatase inhibitors or aromatase inhibitors in combination with CDK4/6 inhibition [184] (table 2). In phase 2 data, fulvestrant (a selective oestrogen degrader—SERD (NCT03455270)) was combined with non-selective FGFR1–3 inhibitor dovitinib in hormone receptor-positive and *FGFR1*-amplified post-menopausal patients who had relapsed on or shortly after endocrine therapy. The study was slow to recruit owing to low identification rate of *FGFR1* amplification in the study cohort, and terminated early, with a lower number than expected survival events in the dovitinib arm. In the non-selected study population, there was no survival benefit on the addition of dovitinib to fulvestrant (median progression-free survival (PFS) 5.5 months in both placebo and dovitinib group). In the *FGFR1*-amplified cohort, there was a modest survival benefit (10.9 months dovitinib arm versus 5.5 months placebo), which met pre-defined superiority criteria [241]. A comparable study using the non-selective FGFR1–3 inhibitor lucatinib in combination with fulvestrant in post-menopausal women after disease relapse on endocrine therapy was again terminated early owing to slow recruitment (18 patients in total received drug) [242]. In this study, a partial response was

observed in 3/18 patients. However, 78% of patients developed grade 3 hypertension, necessitating dose reduction, which is a likely side-effect from co-inhibition of the VEGF axis [242].

Turning towards selective FGFR tyrosine kinase inhibition, two trials using AZD4547 have addressed the question of acquired endocrine resistance in hormone receptor-positive metastatic breast cancer. In RADICAL (NCT01791985), 58 post-menopausal women, who had developed progressive disease with aromatase inhibitors letrozole or anastrozole, were given AZD4547 alongside their pre-existing endocrine therapy, with an aim to re-sensitize to endocrine treatment. At 28 weeks, there were two partial responses to combination therapy and 11 patients had stable disease. Combination treatment was tolerable, with frequently reported side effects including hyperphosphataemia, hair loss and nausea. In the GLOW clinical trial (NCT01202591), post-menopausal metastatic breast cancer patients, who had progressed on first-line endocrine therapy, were offered AZD4547, in combination with exemestane (an irreversible steroidal aromatase inhibitor) or fulvestrant, using different dosing strategies. On this occasion, patients were pre-screened for FGFR1 polysomy (FISH4/5) or gene amplification (FISH6), using *in situ* hybridization assessment in local laboratories before study entry. However, the low number of eligible patients led to slow recruitment and early termination of the study after 40 patients (initial planned cohort 127 patients) based on commercial decision-making. Adverse events listed included anaemia, alopecia, hyperphosphataemia and anorexia. Monitoring for eye disorders was undertaken based on pre-clinical data. Dry eyes or excess lacrimation was the most common listed event and mild in nature, in this limited study. AZD4547 was subsequently licensed by Astra Zeneca to Abbisko in 2019 for further research and development.

By contrast, FOENIX (NCT04024436), a phase 2 clinical trial of futibatinib in hormone receptor-positive or triple negative metastatic breast cancer is recruiting well, with a target accrual of 168 patients, across diverse geographical regions. Cohort 4 of this study assesses the utility of combination therapy with fulvestrant in *FGFR1*-amplified hormone receptor-positive cancer, with results anticipated to be available in 2023/2024.

Two FGFR inhibitors are currently undergoing assessment for efficacy in combination with CDK inhibitors and endocrine therapy in hormone receptor-positive breast cancer in small phase 1 trials. Erdafinitib (JNJ-42756493) is a small molecule pan-FGFR pathway inhibitor that has recently gained FDA approval in urothelial cancers. The study schedule in *FGFR*-amplified breast cancer (NCT03238196) is to recruit 35 patients to assess efficacy and safety in combination with fulvestrant and palbociclib (after prior disease progression on aromatase inhibition). Secondary endpoints include predictive biomarker evaluation to aid patient selection, putatively based on amplification status of FGFR1–4, CDK4 or 6, and cyclin D1/2 and also mutation status of RB1 and ESR. Infigratinib (BGJ-398), a selective FGFR1–3 inhibitor, is in early stage of evaluation for efficacy and tolerability in metastatic breast cancer. Study design includes expansion to combination therapy with tamoxifen or fulvestrant/palbociclib as potential therapeutic co-targets (NCT01928459).

Using another therapeutic approach, FIGHT 101 (NCT02393248) is currently evaluating the addition of pemigatinib to a number of well-characterized cytotoxic

Table 2. Clinical trials of FGFR inhibitors and potential combination therapy in breast cancer. PFS, progression-free survival; CBR, clinical benefit rate; ORR, overall response rate; TEAE, treatment-emergent adverse events; MTD, maximum tolerated dose; DLT, dose-limiting toxicity; RP2D, recommended phase 2 dose.

trial identifier	phase	trial design	combination therapy	primary endpoints	current status
dovitinib					
NCT01528345; start date February 2012	2	dovitinib	fulvestrant	PFS	early study termination; results available
debio-1347					
NCT03344536; start date November 2017	1b/2	open label, non-randomized FGFR-amplified ER+ metastatic breast cancer	fulvestrant	DLT (phase 1), ORR (phase 2)	active, not recruiting; estimated completion date August 2021
INCB054828 (pemigatinib)					
NCT02393248 (FIGHT 101); start date March 2019	Phase 1/2	open label, dose-escalation, safety and tolerability study, 201 participants	gemcitabine + cisplatin + pemigatinib, pembrolizumab + pemigatinib, docetaxel + pemigatinib, trastuzumab + pemigatinib, INCMGA00012 + pemigatinib	MTD, pharmacodynamics as monotherapy and in combination	active, not recruiting; estimated completion date December 2021
AZD4547					
NCT01202591 (GLOW); start date September 2010	2	open label randomized trial in ER+ breast cancer patients with FGFR1 polysomy (FISH4/5) or gene amplification (FISH 6)	fulvestrant, exemestane	safety and tolerability	completed; results available
NCT01791985 (RADICAL); start date February 2013	1b/2	open label AZD4547 in combination with either anastrozole or letrozole in ER+ breast cancer patients progressing on these aromatase inhibitors	anastrozole, letrozole	safety and tolerability	completed; results available
JNJ-42756493 (erdafitinib)					
NCT03238196; start date August 2017	1b	open label, non-randomized in 35 patients with ER+/ HER2-/-FGFR- amplified MBC	fulvestrant, palbociclib	safety and tolerability of combination therapy	active, not recruiting; estimated completion date December 2022

(Continued.)

Table 2. (Continued.)

trial identifier	phase	trial design	combination therapy	primary endpoints	current status
TAS-120 (futibatinib)					
NCT04024436 (FOENIX); start date July 2019	2	open label non-randomized cohort design 168 patients: Cohort 2— TNBC measurable disease, FGFR2 amplification; Cohort 3—HR+ HER2— or TNBC non-measurable disease, FGFR2 amplification; cohort 4— HR+ HER2— measurable disease, FGFR1 amplification	fulvestrant	ORR, CBR and PFS	currently recruiting; estimated completion date June 2023
BGJ398 (infigratinib) (FGFR1–3-selective)					
NCT04504331; start date August 2020	1	open label first in- combination clinical trial, 10 participants, HR+, HER2—, FGFR altered advanced breast cancer	tamoxifen or fulvestrant+ palbociclib	DLT	currently recruiting; estimated completion date October 2023

chemotherapeutics (gemcitabine, cisplatin, docetaxel), HER2-targeted therapy (trastuzumab) and immunotherapy (pembrolizumab) across solid tumours, including breast cancer. The interaction between inhibition of the FGFR pathway with HER2-targeted therapy and immunotherapy, is awaited with some interest.

7.2. FGFR inhibitors: tolerability and toxicity

Apart from efficacy, a key consideration in drug development of molecular-targeted therapies (MTTs) is patient tolerability and drug toxicity. Drug toxicity can occur as a result of 'on-target, off-cancer' effects or idiosyncratic 'off-target' effects of the drug. Drug tolerability, the ability of a patient to maintain quality of life while on an effective anti-cancer therapy, is a crucial issue, particularly in the context of declining fitness (performance status) with metastatic disease. Germline FGFR mutations are associated with defects in bone development and phosphate metabolism. This has led to increased monitoring of bone metabolism and associated ectopic mineralization with FGFR inhibitors in pre-clinical and clinical studies. However, to date most phase 1 and phase 2 clinical trials have reported side effects of FGFR inhibition to be mild or moderate, with more common patient reported symptoms—including dry skin, dry mouth, nausea and diarrhoea. Ophthalmological assessment is built into patient pathways, to ensure early recognition of rare corneal or retinal effects of FGFR inhibitors. In terms of laboratory results, mild–moderate elevation of plasma phosphate (hyperphosphataemia) and liver enzymes has been commonly reported, well mitigated by a robust clinical care plan. Increased specificity, avoiding

VEGFR co-inhibition, has increased tolerability and reduced adverse events. Similarly, avoiding FGFR4 co-inhibition has reduced unpleasant gastrointestinal symptoms such as diarrhoea. In pre-clinical studies, FGFR inhibition with small molecule inhibitors has been associated with embryonic lethality in rodents and therefore effective contraception is mandated with FGFR inhibitors for patients of child-bearing age and their partners. Further safety data regarding rarer side effects of FGFR small molecule inhibitors will be forthcoming with reporting of large-scale phase 2 trials [3].

8. Conclusion and perspectives

In the last few years, large-scale studies based on new technologies have revealed how drivers of breast cancer, including FGFRs, their ligands and signalling partners, are dysregulated [243]. Here, we have discussed the presence of various genomic alterations, the lack of signalling regulation, and impaired paracrine or autocrine activation in the context of FGFR signalling and in the context of ongoing clinical trials. Our increased understanding of these mechanisms has implications for selecting and improving anti-breast cancer therapies where FGFRs are dysregulated. However, despite the amount of available information there are still several aspects of FGFR signalling in breast cancer that are worth further investigation, from both a cellular and a clinical perspective.

8.1. What is missing from a signalling perspective?

Little is known about the specific role of the splicing variants of *FGFR* genes in breast cancer initiation, development or

therapeutic targeting [244]. Given the variety of phenotypes of mice knocked-out for *Fgfr* isoforms [4], the differential expression and role of the 'b' and 'c' variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4). Several recent publications have correlated members of all the FGF subfamilies, and not only the well-characterized FGF7 subfamily [2], to diverse aspects of breast cancer development. This information may be used to uncover which FGFR isoforms are most likely to be activated in different breast cancer subtypes, in addition to available data on the status of the gene of each FGFR in that subtype [3]. For instance, there are indications that FGFR3 plays a role in ER-positive tumours despite its low expression in clinical samples [219]. The FGFR3 ligand FGF8 has been associated with increased proliferation and cell cycle progression in ER-positive tumours [164,165]. It would be therefore worth investigating the correlation between FGF8 and the FGFR3c or the FGFR3b isoform [246,247], besides focusing on the autocrine role of FGF8 through FGFR1 and FGFR4 in epithelial cells. It would be also worth investigating the switch between epithelial 'b' and mesenchymal 'c' isoforms, for instance in the case of the *FGFR2* gene, as this switch contributes to changes in ligand binding and intracellular signalling, as also shown in prostate cancer [248,249]. To decipher the contribution of each FGF/FGFR pair to breast cancer progression there is an unmet need for specific biochemical tools to detect FGFR isoforms and for novel methods—including advanced single-cell mRNA sequencing, quantitative phosphoproteomics and proteogenomic and high-resolution imaging—to be performed in breast cancer models grown in three-dimensional culture or in patient-derived organoids [225]. A complete understanding of the role of FGFR signalling in breast cancer biology and of how FGFR signalling architecture adapts during breast cancer progression [250] or treatment with canonical strategies will then pave the way for discovering or improving novel strategies to benefit breast cancer patients. For instance, the use either of certain FGFs as therapeutics or of more specific ligand-trap molecules

and isoform-specific FGFR inhibitors still needs further optimization [2,133,251–254].

8.2. What is missing from a clinical perspective?

To date, FGFR inhibitors have shown promising clinical activity in tissue agnostic, biomarker-driven 'basket' clinical trials and tissue-specific 'umbrella' trials, including exciting response rates in previously treatment-recalcitrant cancers such as cholangiocarcinoma [238,255,256]. In breast cancer, the clinical incidence of *FGFR1* amplification is 10% and that of *FGFR2* amplification is approximately 2%, and these amplifications are seen across all clinical subtypes. Point mutations in FGFR receptors are less frequent. On a practical level, this necessitates identification of a potentially treatment-sensitive patient cohort from the larger breast cancer population by screening for FGFR amplification/mutation. Screening large numbers of patients is arduous, time-consuming and currently non-routine outside a clinical trial or in early disease. This therefore represents a potential barrier to uptake of FGFR inhibitors. Approval and adoption of FGFR inhibitors in breast cancer will stand or fall on the results of large-scale phase 2/3 trials of the use of FGFR small molecule inhibitors as monotherapy or combination therapy in breast cancer (tables 1 and 2). To date, toxicity has been predictable and manageable within clinical care plans for patients with a reasonable fitness level. An area of significant interest is the role of FGFR inhibitors in the endocrine-resistant breast cancer population, as discussed above.

Data accessibility. This article has no additional data.

Authors' contributions. C.F.: conceptualization, funding acquisition, visualization, writing—original draft, writing—review and editing; C.S.O.: conceptualization, writing—original draft, writing—review and editing. Both authors gave final approval for publication.

Competing interests. We declare we have no competing interests.

Funding. Research in the C.F. lab is supported by the Wellcome Trust (WT Sir Henry Dale Fellowships 107636/Z/15/Z and 107636/Z/15/A), the Biotechnology and Biological Sciences Research Council (grant no. BB/R015864/1) and the Medical Research Council (grant no. MR/T016043/1).

Acknowledgements. We thank all the members of our laboratories for suggestions and discussion.

References

- Hanahan D, Weinberg RA. 2011 Hallmarks of cancer: the next generation. *Cell* **144**, 646–674. (doi:10.1016/j.cell.2011.02.013)
- Rivetti S, Chen C, Chen C, Bellusci S. 2020 Fgf10/Fgfr2b signaling in mammary gland development, homeostasis, and cancer. *Front. Cell Dev. Biol.* **8**, 415. (doi:10.3389/fcell.2020.00415)
- Navid S, Fan C, Flores-Villanueva PO, Generali D, Li Y. 2020 The fibroblast growth factor receptors in breast cancer: from oncogenesis to better treatments. *Int. J. Mol. Sci.* **21**, 2011. (doi:10.3390/ijms21062011)
- Ornitz DM, Itoh N. 2015 The fibroblast growth factor signaling pathway. *Wiley Interdiscip. Rev. Dev. Biol.* **4**, 215–266. (doi:10.1002/wdev.176)
- Templeton AJ, Diez-Gonzalez L, Ace O, Vera-Badillo F, Seruga B, Jordan J, Amir E, Pandiella A, Ocana A. 2014 Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. *Cancer Treat. Rev.* **40**, 1048–1055. (doi:10.1016/j.ctrv.2014.08.003)
- Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. 2018 Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. *Mol. Cancer* **17**, 34. (doi:10.1186/s12943-018-0797-x)
- Lemmon MA, Schlessinger J. 2010 Cell signaling by receptor tyrosine kinases. *Cell* **141**, 1117–1134. (doi:10.1016/j.cell.2010.06.011)
- Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. 2016 Tumor-associated stromal cells as key contributors to the tumor microenvironment. *Breast Cancer Res.* **18**, 84. (doi:10.1186/s13058-016-0740-2)
- Farrell B, Breeze AL. 2018 Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting. *Biochem. Soc. Trans.* **46**, 1753–1770. (doi:10.1042/BST20180004)
- Ferguson HR, Smith MP, Francavilla C. 2021 Fibroblast growth factor receptors (FGFRs) and noncanonical partners in cancer signaling. *Cells* **10**, 1201. (doi:10.3390/cells10051201)
- Francavilla C *et al.* 2013 Functional proteomics defines the molecular switch underlying FGF receptor trafficking and cellular outputs. *Mol. Cell* **51**, 707–722. (doi:10.1016/j.molcel.2013.08.002)
- Furdui CM, Lew ED, Schlessinger J, Anderson KS. 2006 Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered

- reaction. *Mol. Cell* **21**, 711–717. (doi:10.1016/j.molcel.2006.01.022)
13. Lew ED, Furdul CM, Anderson KS, Schlessinger J. 2009 The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. *Sci. Signal.* **2**, ra6. (doi:10.1126/scisignal.2000021)
 14. Brewer JR, Mazot P, Soriano P. 2016 Genetic insights into the mechanisms of FGF signaling. *Genes Dev.* **30**, 751–771. (doi:10.1101/gad.277137.115)
 15. Ong SH, Guy GR, Hadari YR, Laks S, Gotoh N, Schlessinger J, Lax I. 2000 FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. *Mol. Cell. Biol.* **20**, 979–989. (doi:10.1128/MCB.20.3.979-989.2000)
 16. Kanazawa S *et al.* 2010 bFGF regulates PI3-kinase-Rac1-JNK pathway and promotes fibroblast migration in wound healing. *PLoS ONE* **5**, e12228. (doi:10.1371/journal.pone.0012228)
 17. Tan Y, Rouse J, Zhang A, Cariati S, Cohen P, Comb MJ. 1996 FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. *EMBO J.* **15**, 4629–4642. (doi:10.1002/j.1460-2075.1996.tb00840.x)
 18. Tsang M, Dawid IB. 2004 Promotion and attenuation of FGF signaling through the Ras-MAPK pathway. *Sci. Signal.* **2004**, e17. (doi:10.1126/stke.2282004pe17)
 19. Brent AE, Tabin CJ. 2004 FGF acts directly on the somitic tendon progenitors through the Ets transcription factors Pea3 and Erm to regulate scleraxis expression. *Development* **131**, 3885–3896. (doi:10.1242/dev.01275)
 20. Wong ES, Fong CW, Lim J, Yusoff P, Low BC, Langdon WY, Guy GR. 2002 Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. *EMBO J.* **21**, 4796–4808. (doi:10.1093/emboj/cdf493)
 21. Zhou L, Talebian A, Meakin SO. 2015 The signaling adapter, FRS2, facilitates neuronal branching in primary cortical neurons via both Grb2- and Shp2-dependent mechanisms. *J. Mol. Neurosci.* **55**, 663–677. (doi:10.1007/s12031-014-0406-4)
 22. Cunningham DL *et al.* 2020 Differential responses to kinase inhibition in FGFR2-addicted triple negative breast cancer cells: a quantitative phosphoproteomics study. *Scient. Rep.* **10**, 7950. (doi:10.1038/s41598-020-64534-y)
 23. Pui HP, Saga Y. 2017 Gonocytes-to-spermatogonia transition initiates prior to birth in murine testes and it requires FGF signaling. *Mech. Dev.* **144**, 125–139. (doi:10.1016/j.mod.2017.03.002)
 24. Padua RR, Merle PL, Doble BW, Yu CH, Zahradka P, Pierce GN, Panagia V, Kardami E. 1998 FGF-2-induced negative inotropism and cardioprotection are inhibited by chelerythrine: involvement of sarcolemmal calcium-independent protein kinase C. *J. Mol. Cell. Cardiol.* **30**, 2695–2709. (doi:10.1006/jmcc.1998.0832)
 25. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. 2000 Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. *Oncogene* **19**, 3309–3320. (doi:10.1038/sj.onc.1203650)
 26. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. 1996 Receptor specificity of the fibroblast growth factor family. *J. Biol. Chem.* **271**, 15 292–15 297. (doi:10.1074/jbc.271.25.15292)
 27. Zhang X, Ibrahim OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. 2006 Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. *J. Biol. Chem.* **281**, 15 694–15 700. (doi:10.1074/jbc.M601252200)
 28. Hamilton WB, Mosesson Y, Monteiro RS, Emdal KB, Knudsen TE, Francavilla C, Barkai N, Olsen JV, Brickman JM. 2019 Dynamic lineage priming is driven via direct enhancer regulation by ERK. *Nature* **575**, 355–360. (doi:10.1038/s41586-019-1732-z)
 29. Kardami E, Detillieux K, Ma X, Jiang Z, Santiago JJ, Jimenez SK, Cattini PA. 2007 Fibroblast growth factor-2 and cardioprotection. *Heart Fail. Rev.* **12**, 267–277. (doi:10.1007/s10741-007-9027-0)
 30. Kato S, Sekine K. 1999 FGF–FGFR signaling in vertebrate organogenesis. *Cell. Mol. Biol.* **45**, 631–638.
 31. Mailleux AA *et al.* 2002 Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. *Development* **129**, 53–60. (doi:10.1242/dev.129.1.53)
 32. Muller AK, Meyer M, Werner S. 2012 The roles of receptor tyrosine kinases and their ligands in the wound repair process. *Semin. Cell Dev. Biol.* **23**, 963–970. (doi:10.1016/j.semcdb.2012.09.015)
 33. Naye F, Voz ML, Detry N, Hammerschmidt M, Peers B, Manfroid I. 2012 Essential roles of zebrafish *bmp2a*, *fgf10*, and *fgf24* in the specification of the ventral pancreas. *Mol. Biol. Cell.* **23**, 945–954. (doi:10.1091/mbc.e11-08-0664)
 34. Ohuchi H *et al.* 1997 The mesenchymal factor, FGF10, initiates and maintains the outgrowth of the chick limb bud through interaction with FGF8, an apical ectodermal factor. *Development* **124**, 2235–2244. (doi:10.1242/dev.124.11.2235)
 35. Trokovic R, Jukkola T, Saarimäki J, Peltopuro P, Naserke T, Weisenhorn DM, Trokovic N, Wurst W, Partanen J. 2005 Fgfr1-dependent boundary cells between developing mid- and hindbrain. *Dev. Biol.* **278**, 428–439. (doi:10.1016/j.ydbio.2004.11.024)
 36. Wang J, Rhee S, Palaria A, Tremblay KD. 2015 FGF signaling is required for anterior but not posterior specification of the murine liver bud. *Dev. Dyn.* **244**, 431–443. (doi:10.1002/dvdy.24215)
 37. Yamanaka Y, Lanner F, Rossant J. 2010 FGF signal-dependent segregation of primitive endoderm and epiblast in the mouse blastocyst. *Development* **137**, 715–724. (doi:10.1242/dev.043471)
 38. Itoh N. 2010 Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. *Cell Tissue Res.* **342**, 1–11. (doi:10.1007/s00441-010-1024-2)
 39. Li X. 2019 The FGF metabolic axis. *Front. Med.* **13**, 511–530. (doi:10.1007/s11684-019-0711-y)
 40. Goldfarb M. 2005 Fibroblast growth factor homologous factors: evolution, structure, and function. *Cytokine Growth Factor Rev.* **16**, 215–220. (doi:10.1016/j.cytogfr.2005.02.002)
 41. König HG, Fenner BJ, Byrne JC, Schwaborn RF, Bernas T, Jefferies CA, Pohn JH. 2012 Fibroblast growth factor homologous factor 1 interacts with NEMO to regulate NF- κ B signaling in neurons. *J. Cell Sci.* **125**, 6058–6070. (doi:10.1242/jcs.111880)
 42. Schoorlemmer J, Goldfarb M. 2002 Fibroblast growth factor homologous factors and the islet brain-2 scaffold protein regulate activation of a stress-activated protein kinase. *J. Biol. Chem.* **277**, 49 111–49 119. (doi:10.1074/jbc.M205520200)
 43. Wu QF, Yang L, Li S, Wang Q, Yuan XB, Gao X, Bao L, Zhang X. 2012 Fibroblast growth factor 13 is a microtubule-stabilizing protein regulating neuronal polarization and migration. *Cell* **149**, 1549–1564. (doi:10.1016/j.cell.2012.04.046)
 44. Li Q, Zhai Z, Li J. 2020 Fibroblast growth factor homologous factors are potential ion channel modifiers associated with cardiac arrhythmias. *Eur. J. Pharmacol.* **871**, 172920. (doi:10.1016/j.ejphar.2020.172920)
 45. Keegan K, Johnson DE, Williams LT, Hayman MJ. 1991 Characterization of the FGFR-3 gene and its gene product. *Ann. NY Acad. Sci.* **638**, 400–402. (doi:10.1111/j.1749-6632.1991.tb49052.x)
 46. Partanen J, Makela TP, Eerola E, Korhonen J, Hirvonen H, Claesson-Welsh L, Alitalo K. 1991 FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. *EMBO J.* **10**, 1347–1354. (doi:10.1002/j.1460-2075.1991.tb07654.x)
 47. Reich-Slotky R, Bonneh-Barkay D, Shaoul E, Bluma B, Svahn CM, Ron D. 1994 Differential effect of cell-associated heparan sulfates on the binding of keratinocyte growth factor (KGF) and acidic fibroblast growth factor to the KGF receptor. *J. Biol. Chem.* **269**, 32 279–32 285. (doi:10.1016/S0021-9258(18)31632-6)
 48. Trueb B. 2011 Biology of FGFR1, the fifth fibroblast growth factor receptor. *Cell. Mol. Life Sci.* **68**, 951–964. (doi:10.1007/s00018-010-0576-3)
 49. Chellaiath AT, McEwen DG, Werner S, Xu J, Ornitz DM. 1994 Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. *J. Biol. Chem.* **269**, 11 620–11 627. (doi:10.1016/S0021-9258(19)78170-8)
 50. Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AM, Aaronson SA. 1992 Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. *Proc. Natl Acad. Sci. USA* **89**, 246–250. (doi:10.1073/pnas.89.1.246)
 51. Yeh BK, Igarashi M, Eliseenkova AV, Plotnikov AN, Sher I, Ron D, Aaronson SA, Mohammadi M. 2003 Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. *Proc. Natl Acad. Sci. USA* **100**, 2266–2271. (doi:10.1073/pnas.0436500100)

52. Itoh N, Ohta H, Konishi M. 2015 Endocrine FGFs: evolution, physiology, pathophysiology, and pharmacotherapy. *Front. Endocrinol.* **6**, 154. (doi:10.3389/fendo.2015.00154)
53. Ornitz DM. 2000 FGFs, heparan sulfate and FGFRs: complex interactions essential for development. *Bioessays* **22**, 108–112. (doi:10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M)
54. Belov AA, Mohammadi M. 2013 Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. *Cold Spring Harb. Perspect. Biol.* **5**, a015958. (doi:10.1101/chspect.a015958)
55. Makarenkova HP, Hoffman MP, Beenken A, Eliseenkova AV, Meech R, Tsau C, Patel VN, Lang RA, Mohammadi M. 2009 Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis. *Sci. Signal.* **2**, ra55. (doi:10.1126/scisignal.2000304)
56. Thotakura S, Basova L, Makarenkova HP. 2019 FGF gradient controls boundary position between proliferating and differentiating cells and regulates lacrimal gland growth dynamics. *Front. Genet.* **10**, 362. (doi:10.3389/fgene.2019.00362)
57. Gattineni J, Alphonse P, Zhang Q, Mathews N, Bates CM, Baum M. 2014 Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. *Am. J. Physiol. Renal Physiol.* **306**, F351–F358. (doi:10.1152/ajprenal.00232.2013)
58. Ito S, Kinoshita S, Shiraihi N, Nakagawa S, Sekine S, Fujimori T, Nabeshima YI. 2000 Molecular cloning and expression analyses of mouse β -klotho, which encodes a novel Klotho family protein. *Mech. Dev.* **98**, 115–119. (doi:10.1016/S0925-4773(00)00439-1)
59. Goetz R *et al.* 2012 Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. *Mol. Cell Biol.* **32**, 1944–1954. (doi:10.1128/MCB.06603-11)
60. Korc M, Friesel RE. 2009 The role of fibroblast growth factors in tumor growth. *Curr. Cancer Drug Targets* **9**, 639–651. (doi:10.2174/156800909789057006)
61. Li X, Wang C, Xiao J, McKeenan WL, Wang F. 2016 Fibroblast growth factors, old kids on the new block. *Semin. Cell Dev. Biol.* **53**, 155–167. (doi:10.1016/j.semcdb.2015.12.014)
62. Zinkle A, Mohammadi M. 2019 Structural biology of the FGF7 subfamily. *Front. Genet.* **10**, 102. (doi:10.3389/fgene.2019.00102)
63. Francavilla C, Cattaneo P, Berezin V, Bock E, Ami D, de Marco A, Christofori G, Cavallaro U. 2009 The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking. *J. Cell Biol.* **187**, 1101–1116. (doi:10.1083/jcb.200903030)
64. Kon E, Calvo-Jimenez E, Cossard A, Na Y, Cooper JA, Jossin Y. 2019 N-cadherin-regulated FGFR ubiquitination and degradation control mammalian neocortical projection neuron migration. *eLife* **8**, e47673. (doi:10.7554/eLife.47673)
65. Korsensky L, Ron D. 2016 Regulation of FGF signaling: recent insights from studying positive and negative modulators. *Semin. Cell Dev. Biol.* **53**, 101–114. (doi:10.1016/j.semcdb.2016.01.023)
66. Zivotic M, Tampe B, Muller G, Muller C, Lipkovski A, Xu X, Nyamsuren G, Zeisberg M, Markovic-Lipkovski J. 2018 Modulation of NCAM/FGFR1 signaling suppresses EMT program in human proximal tubular epithelial cells. *PLoS ONE* **13**, e0206786. (doi:10.1371/journal.pone.0206786)
67. Latko M, Czyrek A, Porebska N, Kucinska M, Otlewski J, Zakrzewska M, Opalinski L. 2019 Crosstalk between fibroblast growth factor receptors and other cell surface proteins. *Cells* **8**, 455. (doi:10.3390/cells8050455)
68. Smith MP *et al.* 2021 Reciprocal priming between receptor tyrosine kinases at recycling endosomes orchestrates cellular signalling outputs. *EMBO J.* **40**, e107182. (doi:10.15252/emboj.2020107182)
69. Zinkle A, Mohammadi M. 2019 A threshold model for receptor tyrosine kinase signaling specificity and cell fate determination. *Front. Genet.* **12**, 102. (doi:10.3389/fgene.2019.00102)
70. Haugsten EM, Sorensen V, Brech A, Olsnes S, Wesche J. 2005 Different intracellular trafficking of FGF1 endocytosed by the four homologous FGF receptors. *J. Cell Sci.* **118**, 3869–3881. (doi:10.1242/jcs.02509)
71. Belleudi F, Leone L, Nobili V, Raffa S, Francescangeli F, Maggio M, Morrone S, Marchese C, Torrisi MR. 2007 Keratinocyte growth factor receptor ligands target the receptor to different intracellular pathways. *Traffic* **8**, 1854–1872. (doi:10.1111/j.1600-0854.2007.00651.x)
72. Auciello G, Cunningham DL, Tatar T, Heath JK, Rappoport JZ. 2013 Regulation of fibroblast growth factor receptor signalling and trafficking by Src and Eps8. *J. Cell Sci.* **126**, 613–624. (doi:10.1242/jcs.116228)
73. Chioni AM, Grose R. 2012 FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. *J. Cell Biol.* **197**, 801–817. (doi:10.1083/jcb.201108077)
74. Coleman SJ, Chioni AM, Ghallab M, Anderson RK, Lemoine NR, Kocher HM, Grose RP. 2014 Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. *EMBO Mol. Med.* **6**, 467–481. (doi:10.1002/emmm.201302698)
75. Lin CC, Melo FA, Ghosh R, Suen KM, Stagg LJ, Kirkpatrick J, Arold ST, Ahmed Z, Ladbury JE. 2012 Inhibition of basal FGF receptor signaling by dimeric Grb2. *Cell* **149**, 1514–1524. (doi:10.1016/j.cell.2012.04.033)
76. Zakrzewska M, Haugsten EM, Nadratowska-Wesolowska B, Oppelt A, Hausott B, Jin Y, Otlewski J, Wesche J, Wiedlocha A. 2013 ERK-mediated phosphorylation of fibroblast growth factor receptor 1 on Ser777 inhibits signaling. *Sci. Signal.* **6**, ra11. (doi:10.1126/scisignal.2003087)
77. Yang X, Gong Y, Tang Y, Li H, He Q, Gower L, Liaw L, Friesel RE. 2013 Spry1 and Spry4 differentially regulate human aortic smooth muscle cell phenotype via Akt/FoxO/myocardin signaling. *PLoS ONE* **8**, e58746. (doi:10.1371/journal.pone.0058746)
78. Yu XY, Wang XT, Chu YL, Qu HM, Liu J, Zhang YH, Li MJ. 2018 Effect of FGF2 on the activity of SPRYs/DUSP6/ERK signaling pathway in endometrial glandular epithelial cells of endometriosis. *Eur. Rev. Med. Pharmacol. Sci.* **22**, 1554–1568. (doi:10.26355/eurrev_201803_14560)
79. Mathew G, Hannan A, Hertzler-Schaefer K, Wang F, Feng GS, Zhong J, Zhao JJ, Downward J, Zhang X. 2016 Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor. *Proc. Natl Acad. Sci. USA* **113**, 13 156–13 161. (doi:10.1073/pnas.1604450113)
80. Yoo DH, Im YS, Jo EH, Kim BY, Jo HY, Park MH, Koo SK, Kim YO. 2020 Simple differentiation method using FBS identifies DUSP6 as a marker for fine-tuning of FGF-ERK signaling activity in human pluripotent stem cells. *Biochem. Biophys. Res. Commun.* **521**, 375–382. (doi:10.1016/j.bbrc.2019.10.081)
81. Haugsten EM, Malecki J, Bjorklund SM, Olsnes S, Wesche J. 2008 Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis. *Mol. Biol. Cell.* **19**, 3390–3403. (doi:10.1091/mbc.e07-12-1219)
82. Brisken C, Ataca D. 2015 Endocrine hormones and local signals during the development of the mouse mammary gland. *Wiley Interdiscip. Rev. Dev. Biol.* **4**, 181–195. (doi:10.1002/wdev.172)
83. Andl T, Reddy ST, Gaddapara T, Millar SE. 2002 WNT signals are required for the initiation of hair follicle development. *Dev. Cell* **2**, 643–653. (doi:10.1016/S1534-5807(02)00167-3)
84. Veltmaat JM *et al.* 2006 Gli3-mediated somitic Fgf10 expression gradients are required for the induction and patterning of mammary epithelium along the embryonic axes. *Development* **133**, 2325–2335. (doi:10.1242/dev.02394)
85. Parsa S, Ramasamy SK, De Langhe S, Gupte VV, Haigh JJ, Medina D, Bellusci S. 2008 Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling. *Dev. Biol.* **317**, 121–131. (doi:10.1016/j.ydbio.2008.02.014)
86. Al Alam D *et al.* 2015 Evidence for the involvement of fibroblast growth factor 10 in lipofibroblast formation during embryonic lung development. *Development* **142**, 4139–4150. (doi:10.1242/dev.109173)
87. Elo T *et al.* 2017 Ectodysplasin target gene Fgf20 regulates mammary bud growth and ductal invasion and branching during puberty. *Scient. Rep.* **7**, 5049. (doi:10.1038/s41598-017-04637-1)
88. Zhang X, Martinez D, Koledova Z, Qiao G, Streuli CH, Lu P. 2014 FGF ligands of the postnatal mammary stroma regulate distinct aspects of epithelial morphogenesis. *Development* **141**, 3352–3362. (doi:10.1242/dev.106732)
89. Sumbal J, Koledova Z. 2019 FGF signaling in mammary gland fibroblasts regulates multiple fibroblast functions and mammary epithelial morphogenesis. *Development* **146**, dev185306. (doi:10.1242/dev.185306)
90. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J,

- Cardoso F. 2019 Breast cancer. *Nat. Rev. Dis. Primers* **5**, 66. (doi:10.1038/s41572-019-0111-2)
91. Perou CM *et al.* 2000 Molecular portraits of human breast tumours. *Nature* **406**, 747–752. (doi:10.1038/35021093)
92. Camp NJ, Madsen MJ, Herranz J, Rodriguez-Lescure A, Ruiz A, Martin M, Bernard PS. 2019 Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer. *Breast Cancer Res. Treat.* **175**, 129–139. (doi:10.1007/s10549-018-05097-5)
93. Sorlie T *et al.* 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc. Natl Acad. Sci. USA* **100**, 8418–8423. (doi:10.1073/pnas.0932692100)
94. Cardoso F *et al.* 2016 70-gene signature as an aid to treatment decisions in early-stage breast cancer. *N. Engl. J. Med.* **375**, 717–729. (doi:10.1056/NEJMoa1602253)
95. Sparano JA. 2018 Gene expression assays in early-stage breast cancer. *Oncology* **32**, 510–512.
96. Rothwell DG *et al.* 2019 Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. *Nat. Med.* **25**, 738–743. (doi:10.1038/s41591-019-0380-z)
97. Zhou Z, Wu B, Tang X, Ke R, Zou Q. 2020 Comprehensive analysis of fibroblast growth factor receptor (FGFR) family genes in breast cancer by integrating online databases and bioinformatics. *Med. Sci. Monit.* **26**, e923517. (doi:10.12659/MSM.923517.)
98. Issa A, Gill JW, Heideman MR, Sahin O, Wiemann S, Dey JH, Hynes NE. 2013 Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. *Breast Cancer Res.* **15**, R8. (doi:10.1186/bcr3379)
99. Sharpe R *et al.* 2011 FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both *in vitro* and *in vivo*. *Clin. Cancer Res.* **17**, 5275–5286. (doi:10.1158/1078-0432.CCR-10-2727)
100. Sootome H *et al.* 2020 Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. *Cancer Res.* **80**, 4986–4997. (doi:10.1158/0008-5472.CAN-19-2568)
101. Zhao Q, Parris AB, Howard EW, Zhao M, Ma Z, Guo Z, Xing Y, Yang X. 2017 FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice. *Scient. Rep.* **7**, 11306. (doi:10.1038/s41598-017-11751-7)
102. Tarkkonen KM, Nilsson EM, Kahkonen TE, Dey JH, Heikkila JE, Tuomela JM, Liu Q, Hynes NE, Harkonen PL. 2012 Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. *PLoS ONE* **7**, e49970. (doi:10.1371/journal.pone.0049970)
103. Adnane J, Gaudray P, Dionne CA, Crumley G, Jaye M, Schlessinger J, Jeanteur P, Birnbaum D, Theillet C. 1991 BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. *Oncogene* **6**, 659–663.
104. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. 2016 The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. *Clin. Cancer Res.* **22**, 259–267. (doi:10.1158/1078-0432.CCR-14-3212)
105. Hunter DJ *et al.* 2007 A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nat. Genet.* **39**, 870–874. (doi:10.1038/ng2075)
106. Freitag CE, Mei P, Wei L, Parwani AV, Li Z. 2020 Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations. *Hum. Pathol.* **102**, 94–103. (doi:10.1016/j.humpath.2020.05.005)
107. van Geelen CT *et al.* 2020 Clinical implications of prospective genomic profiling of metastatic breast cancer patients. *Breast Cancer Res.* **22**, 91. (doi:10.1186/s13058-020-01328-0)
108. Xie N *et al.* 2020 *FGFR* aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients. *Ther. Adv. Med. Oncol.* **12**, 1758835920915305. (doi:10.1177/1758835920915305)
109. Brunello E *et al.* 2012 *FGFR-1* amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. *J. Exp. Clin. Cancer Res.* **31**, 103. (doi:10.1186/1756-9966-31-103)
110. Mao P *et al.* 2020 Acquired *FGFR* and *FGF* alterations confer resistance to estrogen receptor (ER) targeted therapy in ER⁺ metastatic breast cancer. *Clin. Cancer Res.* **26**, 5974–5989. (doi:10.1158/1078-0432.CCR-19-3958)
111. De Mattos-Arruda L *et al.* 2019 The genomic and immune landscapes of lethal metastatic breast cancer. *Cell Rep.* **27**, 2690–2708. (doi:10.1016/j.celrep.2019.04.098)
112. Garcia-Recio S *et al.* 2020 *FGFR4* regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. *J. Clin. Invest.* **130**, 4871–4887. (doi:10.1172/JCI130323)
113. Turner N, Grose R. 2010 Fibroblast growth factor signalling: from development to cancer. *Nat. Rev. Cancer.* **10**, 116–129. (doi:10.1038/nrc2780)
114. Hosaka K *et al.* 2020 Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors. *Nat. Commun.* **11**, 3704. (doi:10.1038/s41467-020-17525-6)
115. van der Spek YM, Kroep JR, Tollenaar R, Mesker WE. 2020 Chemotherapy resistance and stromal targets in breast cancer treatment: a review. *Mol. Biol. Rep.* **47**, 8169–8177. (doi:10.1007/s11033-020-05853-1.)
116. Eiro N, Gonzalez L, Martinez-Ordonez A, Fernandez-Garcia B, Gonzalez LO, Cid S, Dominguez F, Perez-Fernandez R, Vizoso FJ. 2018 Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis. *Cell Oncol.* **41**, 369–378. (doi:10.1007/s13402-018-0371-y)
117. Wu X *et al.* 2018 Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts. *Clin. Proteomics* **15**, 21. (doi:10.1186/s12014-018-9197-x)
118. Palakurthi S *et al.* 2019 The combined effect of *FGFR* inhibition and *PD-1* blockade promotes tumor-intrinsic induction of antitumor immunity. *Cancer Immunol. Res.* **7**, 1457–1471. (doi:10.1158/2326-6066.CIR-18-0595)
119. Katoh M. 2016 *FGFR* inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). *Int. J. Mol. Med.* **38**, 3–15. (doi:10.3892/ijmm.2016.2620)
120. Andre F, Cortes J. 2015 Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. *Breast Cancer Res. Treat.* **150**, 1–8. (doi:10.1007/s10549-015-3301-y)
121. Piasecka D, Braun M, Kitowska K, Mieczkowski K, Kordek R, Sadej R, Romanska H. 2019 *FGFs/FGFRs*-dependent signalling in regulation of steroid hormone receptors – implications for therapy of luminal breast cancer. *J. Exp. Clin. Cancer Res.* **38**, 230. (doi:10.1186/s13046-019-1236-6)
122. Johnston CL, Cox HC, Gomm JJ, Coombes RC. 1995 bFGF and aFGF induce membrane ruffling in breast cancer cells but not in normal breast epithelial cells: *FGFR-4* involvement. *Biochem. J.* **306**, 609–616. (doi:10.1042/bj3060609)
123. Zhu H, Duchesne L, Rudland PS, Fernig DG. 2010 The heparan sulfate co-receptor and the concentration of fibroblast growth factor-2 independently elicit different signalling patterns from the fibroblast growth factor receptor. *Cell Commun. Signal.* **8**, 14. (doi:10.1186/1478-811X-8-14)
124. Koledova Z, Sumbal J, Rabata A, de La Bourdonnaye G, Chaloupkova R, Hrdlickova B, Damborsky J, Stepankova V. 2019 Fibroblast growth factor 2 protein stability provides decreased dependence on heparin for induction of *FGFR* signaling and alters *ERK* signaling dynamics. *Front. Cell Dev. Biol.* **7**, 331. (doi:10.3389/fcell.2019.00331)
125. He S, Zhang G, Dong H, Ma M, Sun Q. 2016 *miR-203* facilitates tumor growth and metastasis by targeting fibroblast growth factor 2 in breast cancer. *Oncotargets Ther.* **9**, 6203–6210. (doi:10.2147/OTT.S108712)
126. Suh J, Kim DH, Lee YH, Jang JH, Surh YJ. 2020 Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via *FGFR1* signaling. *Mol. Carcinog.* **59**, 1028–1040. (doi:10.1002/mc.23233)
127. Giulianelli S *et al.* 2019 *FGF2* induces breast cancer growth through ligand-independent activation and recruitment of *ERα* and *PRBΔ4* isoform to *MYC* regulatory sequences. *Int. J. Cancer.* **145**, 1874–1888. (doi:10.1002/ijc.32252)
128. Sahores A *et al.* 2018 Increased high molecular weight *FGF2* in endocrine-resistant breast cancer. *Horm. Cancer* **9**, 338–348. (doi:10.1007/s12672-018-0339-4)
129. Chen J, Zhou Z, Yao Y, Dai J, Zhou D, Wang L, Zhang QQ. 2018 Dipalmitoylphosphatidic acid

- inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1/FGF1/HGF signalling pathway. *J. Cell Mol. Med.* **22**, 4760–4770. (doi:10.1111/jcmm.13727)
130. Incio J *et al.* 2018 Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. *Sci. Transl. Med.* **10**, eaag0945. (doi:10.1126/scitranslmed.aag0945)
131. He XX *et al.* 2018 Humanization of fibroblast growth factor 1 single-chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells. *J. Cell Mol. Med.* **22**, 3259–3263. (doi:10.1111/jcmm.13547)
132. Chudzian J, Szlachcic A, Zakrzewska M, Czub M, Pustula M, Holak TA, Otlewski J. 2018 Specific antibody fragment ligand traps blocking FGF1 activity. *Int. J. Mol. Sci.* **19**, 2470. (doi:10.3390/ijms19092470)
133. Presta M, Chiodelli P, Giacomini A, Rusnati M, Ronca R. 2017 Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. *Pharmacol. Ther.* **179**, 171–187. (doi:10.1016/j.pharmthera.2017.05.013)
134. Penault-Llorca F, Bertucci F, Adelaide J, Parc P, Coulier F, Jacquemier J, Birnbaum D, deLapeyriere O. 1995 Expression of FGF and FGF receptor genes in human breast cancer. *Int. J. Cancer* **61**, 170–176. (doi:10.1002/ijc.2910610205)
135. Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, Fridlyand J, Albertson DG. 2009 Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. *Oncogene* **28**, 1892–1903. (doi:10.1038/onc.2009.34)
136. Hanker AB *et al.* 2017 HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. *Clin. Cancer Res.* **23**, 4323–4334. (doi:10.1158/1078-0432.CCR-16-2287)
137. Fernandez-Nogueira P *et al.* 2020 Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation. *Clin. Cancer Res.* **26**, 1432–1448. (doi:10.1158/1078-0432.CCR-19-0353)
138. Nadarajan K, Balam P, Khoo BY. 2016 MK886 inhibits the pioglitazone-induced anti-invasion of MDA-MB-231 cells is associated with PPAR α / γ , FGF4 and SLOX. *Cytotechnology* **68**, 1771–1787. (doi:10.1007/s10616-015-9930-5)
139. Shi H *et al.* 2016 The oncoprotein HBXIP up-regulates FGF4 through activating transcriptional factor Sp1 to promote the migration of breast cancer cells. *Biochem. Biophys. Res. Commun.* **471**, 89–94. (doi:10.1016/j.bbrc.2016.01.174)
140. Zhang C, Yang T, Jiang H. 2020 miR-511 inhibits proliferation and metastasis of breast cancer cells by targeting FGF4. *J. Gene Med.* **22**, e3168. (doi:10.1002/jgm.3168)
141. Casimiro S *et al.* 2012 Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. *Clin. Exp. Metastasis* **29**, 155–164. (doi:10.1007/s10585-011-9438-0)
142. Huang Y, Wang H, Yang Y. 2018 Expression of fibroblast growth factor 5 (FGF5) and its influence on survival of breast cancer patients. *Med. Sci. Monit.* **24**, 3524–3530. (doi:10.12659/MSM.907798)
143. Wang W *et al.* 2015 Screening a novel FGF3 antagonist peptide with anti-tumor effects on breast cancer from a phage display library. *Mol. Med. Rep.* **12**, 7051–7058. (doi:10.3892/mmr.2015.4248)
144. Sachs N *et al.* 2018 A living biobank of breast cancer organoids captures disease heterogeneity. *Cell* **172**, 373–386. (doi:10.1016/j.cell.2017.11.010)
145. Jacquemier J, Sun ZZ, Penault-Llorca F, Geneix J, Devillard E, Adelaide J, Birnbaum D. 1998 FGF7 protein expression in human breast carcinomas. *J. Pathol.* **186**, 269–274. (doi:10.1002/(SICI)1096-9896(199811)186:3<269::AID-PATH187>3.0.CO;2-G)
146. Nguyen TN, Zang XP, Pento JT. 2002 Keratinocyte growth factor stimulates the migration and proliferation of breast cancer cells in a culture wounding model. *Pharmacol. Res.* **46**, 179–183. (doi:10.1016/S1043-6618(02)00085-3)
147. Palmieri C *et al.* 2003 Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1 β -induced paracrine growth factor for human breast cells. *J. Endocrinol.* **177**, 65–81. (doi:10.1677/joe.0.1770065)
148. Zhu Y *et al.* 2019 Long noncoding RNA Linc00460 promotes breast cancer progression by regulating the miR-489-5p/FGF7/AKT axis. *Cancer Manag. Res.* **11**, 5983–6001. (doi:10.2147/CMAR.S207084)
149. Roldan DB *et al.* 2020 PLAC1 is essential for FGF7/FGFR11b-induced Akt-mediated cancer cell proliferation. *Oncotarget* **11**, 1862–1875. (doi:10.18632/oncotarget.27582)
150. Zang XP, Siwak DR, Nguyen TX, Tari AM, Pento JT. 2004 KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk1,2. *Clin. Exp. Metastasis* **21**, 437–443. (doi:10.1007/s10585-004-2051-8)
151. Piasecka D *et al.* 2016 Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells. *Oncotarget* **7**, 86 011–86 025. (doi:10.18632/oncotarget.13322)
152. Turczyk L *et al.* 2017 FGFR2-driven signaling counteracts tamoxifen effect on ER α -positive breast cancer cells. *Neoplasia* **19**, 791–804. (doi:10.1016/j.neo.2017.07.006)
153. Theodorou V, Boer M, Weigelt B, Jonkers J, van der Valk M, Hilkens J. 2004 Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. *Oncogene* **23**, 6047–6055. (doi:10.1038/sj.onc.1207816)
154. Grigoriadis A *et al.* 2006 Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. *Breast Cancer Res.* **8**, R56. (doi:10.1186/bcr1604)
155. Huijts PE *et al.* 2011 Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10. *Breast Cancer Res.* **13**, R72. (doi:10.1186/bcr2917)
156. Ghossaini M *et al.* 2016 Evidence that the 5p12 variant rs10941679 confers susceptibility to estrogen-receptor-positive breast cancer through FGF10 and MRP530 regulation. *Am. J. Hum. Genet.* **99**, 903–911. (doi:10.1016/j.ajhg.2016.07.017)
157. Grose R, Dickson C. 2005 Fibroblast growth factor signaling in tumorigenesis. *Cytokine Growth Factor Rev.* **16**, 179–186. (doi:10.1016/j.cytogr.2005.01.003)
158. Abolhassani A, Riazi GH, Azizi E, Amanpour S, Muhammadnejad S, Haddadi M, Zekri A, Shirkoobi R. 2014 FGF10: type III epithelial mesenchymal transition and invasion in breast cancer cell lines. *J. Cancer* **5**, 537–547. (doi:10.7150/jca.7797)
159. Campbell TM, Castro MAA, de Oliveira KG, Ponder BAJ, Meyer KB. 2018 ER α binding by transcription factors NFIB and YBX1 enables FGFR2 signaling to modulate estrogen responsiveness in breast cancer. *Cancer Res.* **78**, 410–421. (doi:10.1158/0008-5472.CAN-17-1153)
160. Marsh SK, Bansal GS, Zammit C, Barnard R, Coope R, Roberts-Clarke D, Gomm JJ, Coombes RC, Johnston CL. 1999 Increased expression of fibroblast growth factor 8 in human breast cancer. *Oncogene* **18**, 1053–1060. (doi:10.1038/sj.onc.1202392)
161. Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppanen JA, Harkonen PL. 2001 FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells. *Oncogene* **20**, 2791–2804. (doi:10.1038/sj.onc.1204430)
162. Liu F, You X, Wang Y, Liu Q, Liu Y, Zhang S, Chen L, Zhang X, Ye L. 2014 The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF. *Carcinogenesis* **35**, 1144–1153. (doi:10.1093/carcin/bgu021)
163. Valta MP, Hentunen T, Qu Q, Valve EM, Harjula A, Seppanen JA, Vaananen HK, Harkonen PL. 2006 Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. *Endocrinology* **147**, 2171–2182. (doi:10.1210/en.2005-1502)
164. Masuda H *et al.* 2011 Functional interaction of fibroblast growth factor-8, bone morphogenetic protein and estrogen receptor in breast cancer cell proliferation. *Mol. Cell. Endocrinol.* **343**, 7–17. (doi:10.1016/j.mce.2011.05.037)
165. Nilsson EM, Brokken LJ, Narvi E, Kallio MJ, Harkonen PL. 2012 Identification of fibroblast growth factor-8b target genes associated with early and late cell cycle events in breast cancer cells. *Mol. Cell. Endocrinol.* **358**, 104–115. (doi:10.1016/j.mce.2012.03.009)
166. Yu Z, Lou L, Zhao Y. 2018 Fibroblast growth factor 18 promotes the growth, migration and invasion of MDA-MB-231 cells. *Oncol. Rep.* **40**, 704–714. (doi:10.3892/or.2018.6482)
167. Song N *et al.* 2018 FGF18 enhances migration and the epithelial-mesenchymal transition in breast cancer by regulating Akt/GSK3 β /B-catenin signaling. *Cell Physiol. Biochem.* **49**, 1019–1032. (doi:10.1159/000493286)

168. Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES, Kuperwasser C. 2010 Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. *Proc. Natl Acad. Sci. USA* **107**, 21 737–21 742. (doi:10.1073/pnas.1007863107)
169. Wu Y, Tao L, Liang J, Qiao Y, Liu W, Yu H, Yu X, Liu L. 2020 miR-187-3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression. *Exp. Ther. Med.* **20**, 952–960. (doi:10.3892/etm.2020.8770)
170. Buhmeida A *et al.* 2014 High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast. *Tumour Biol.* **35**, 2817–2824. (doi:10.1007/s13277-013-1374-y)
171. Zhao X, Xu F, Dominguez NP, Xiong Y, Xiong Z, Peng H, Shay C, Teng Y. 2018 FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression. *Mol. Carcinog.* **57**, 1616–1625. (doi:10.1002/mc.22884)
172. Zhang D, Xu X, Ye Q. 2020 Metabolism and immunity in breast cancer. *Front. Med.* **15**, 178–207. (doi:10.1007/s11684-020-0793-6)
173. Akyol M *et al.* 2017 The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy. *Cancer Biomark.* **18**, 441–449. (doi:10.3233/CBM-161507)
174. Ma F, Liu X, Zhou S, Li W, Liu C, Chadwick M, Qian C. 2019 Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop. *Cancer Lett.* **450**, 63–75. (doi:10.1016/j.canlet.2019.02.008)
175. Yang F, Liu YH, Dong SY, Ma RM, Bhandari A, Zhang XH, Wang OC. 2016 A novel long non-coding RNA FGF14-AS2 is correlated with progression and prognosis in breast cancer. *Biochem. Biophys. Res. Commun.* **470**, 479–483. (doi:10.1016/j.bbrc.2016.01.147)
176. Hollern DP, Swiatnicki MR, Rennhack JP, Miskic SA, Matson BC, McAuliff A, Gallo KA, Caron KM, Andrechek ER. 2019 E2F1 drives breast cancer metastasis by regulating the target gene FGF13 and altering cell migration. *Scient. Rep.* **9**, 10718. (doi:10.1038/s41598-019-47218-0)
177. Johnstone CN, Pattison AD, Harrison PF, Powell DR, Lock P, Ernst M, Anderson RL, Beilharz TH. 2020 FGF13 promotes metastasis of triple-negative breast cancer. *Int. J. Cancer* **147**, 230–243. (doi:10.1002/ijc.32874)
178. Voutsadakis IA. 2020 8p11.23 amplification in breast cancer: molecular characteristics, prognosis and targeted therapy. *J. Clin. Med.* **9**, 3079. (doi:10.3390/jcm9103079)
179. Andre F *et al.* 2013 Targeting FGFR with dicitinib (TKI258): preclinical and clinical data in breast cancer. *Clin. Cancer Res.* **19**, 3693–3702. (doi:10.1158/1078-0432.CCR-13-0190)
180. Guagnano V *et al.* 2012 FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. *Cancer Discov.* **2**, 1118–1133. (doi:10.1158/2159-8290.CD-12-0210)
181. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM. 2002 Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. *J. Cell Biol.* **157**, 703–714. (doi:10.1083/jcb.200107119)
182. Reis-Filho JS *et al.* 2006 FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. *Clin. Cancer Res.* **12**, 6652–6662. (doi:10.1158/1078-0432.CCR-06-1164)
183. Turner N *et al.* 2010 FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. *Cancer Res.* **70**, 2085–2094. (doi:10.1158/0008-5472.CAN-09-3746)
184. Formisano L *et al.* 2019 Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. *Nat. Commun.* **10**, 1373. (doi:10.1038/s41467-019-09068-2)
185. Ross DS *et al.* 2020 Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients. *Ann. Oncol.* **31**, 991–1000. (doi:10.1016/j.annonc.2020.04.008)
186. Luqmani YA, Graham M, Coombes RC. 1992 Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. *Br. J. Cancer* **66**, 273–280. (doi:10.1038/bjc.1992.256)
187. Brown WS, Akhand SS, Wendt MK. 2016 FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition. *Oncotarget* **7**, 83 424–83 436. (doi:10.18632/oncotarget.13117)
188. Brown WS, Tan L, Smith A, Gray NS, Wendt MK. 2016 Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer. *Mol. Cancer Ther.* **15**, 2096–2106. (doi:10.1158/1535-7163.MCT-16-0136)
189. Chen Y *et al.* 2016 FGFR antagonist induces protective autophagy in FGFR1-amplified breast cancer cell. *Biochem. Biophys. Res. Commun.* **474**, 1–7. (doi:10.1016/j.bbrc.2016.03.017)
190. Shi Y, Ma Z, Cheng Q, Wu Y, Parris AB, Kong L, Yang X. 2020 FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling. *Biochim. Biophys. Acta Mol. Cell Res.* **1868**, 118877. (doi:10.1016/j.bbamcr.2020.118877)
191. Formisano L *et al.* 2017 Association of FGFR1 with ER α maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer. *Clin. Cancer Res.* **23**, 6138–6150. (doi:10.1158/1078-0432.CCR-17-1232)
192. Bohrer LR, Schwertfeger KL. 2012 Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner. *Mol. Cancer Res.* **10**, 1294–1305. (doi:10.1158/1541-7786.MCR-12-0275)
193. Aukes K, Forsman C, Brady NJ, Astleford K, Blixt N, Sachdev D, Jensen ED, Mansky KC, Schwertfeger KL. 2017 Breast cancer cell-derived fibroblast growth factors enhance osteoclast activity and contribute to the formation of metastatic lesions. *PLoS ONE* **12**, e0185736. (doi:10.1371/journal.pone.0185736)
194. Chen S, Qiu Y, Guo P, Pu T, Feng Y, Bu H. 2018 FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis. *Oncol. Lett.* **15**, 8206–8214. (doi:10.3892/ol.2018.8423)
195. Carene D *et al.* 2020 Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACSO4 and METABRIC studies. *Breast Cancer Res. Treat.* **179**, 387–401. (doi:10.1007/s10549-019-05462-y)
196. Zhao M, Zhuo ML, Zheng X, Su X, Meric-Bernstam F. 2019 FGFR1 β is a driver isoform of FGFR1 alternative splicing in breast cancer cells. *Oncotarget* **10**, 30–44. (doi:10.18632/oncotarget.26530)
197. Golfmann K *et al.* 2018 Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. *Oncogene* **37**, 5682–5693. (doi:10.1038/s41388-018-0380-3)
198. Chen Z *et al.* 2019 C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. *Acta Pharmacol. Sin.* **40**, 823–832. (doi:10.1038/s41401-018-0191-7)
199. Turner N *et al.* 2010 Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. *Oncogene* **29**, 2013–2023. (doi:10.1038/nc.2009.489)
200. Campbell J *et al.* 2016 Large-scale profiling of kinase dependencies in cancer cell lines. *Cell Rep.* **14**, 2490–2501. (doi:10.1016/j.celrep.2016.02.023)
201. Braun M *et al.* 2020 Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma. *Cancers (Basel)* **12**, 2713. (doi:10.3390/cancers12092713)
202. Reintjes N, Li Y, Becker A, Rohmann E, Schmutzler R, Wollnik B. 2013 Activating somatic FGFR2 mutations in breast cancer. *PLoS ONE* **8**, e60264. (doi:10.1371/journal.pone.0060264)
203. Easton DF *et al.* 2007 Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* **447**, 1087–1093. (doi:10.1038/nature05887)
204. Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF, Caldas C, Ponder BA. 2008 Allele-specific up-regulation of *FGFR2* increases susceptibility to breast cancer. *PLoS Biol.* **6**, e108. (doi:10.1371/journal.pbio.0060108)
205. Stacey SN *et al.* 2008 Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat. Genet.* **40**, 703–706. (doi:10.1038/ng.131)
206. Kim S *et al.* 2013 FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells. *PLoS ONE* **8**, e51671. (doi:10.1371/journal.pone.0051671)
207. Zhu X, Asa SL, Ezzat S. 2009 Histone-acetylated control of fibroblast growth factor receptor 2 intron

- 2 polymorphisms and isoform splicing in breast cancer. *Mol. Endocrinol.* **23**, 1397–1405. (doi:10.1210/me.2009-0071)
208. Dankova Z *et al.* 2017 Association of single nucleotide polymorphisms in FGF-RAS/MAP signalling cascade with breast cancer susceptibility. *Gen. Physiol. Biophys.* **36**, 565–572. (doi:10.4149/gpb_2017033)
209. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyrtatos F, Cohen P, Lidereau R, Bieche I. 2006 Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. *Endocr. Relat. Cancer.* **13**, 1109–1120. (doi:10.1677/erc.1.01120)
210. Mulligan AM *et al.* 2011 Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Res.* **13**, R110. (doi:10.1186/bcr3052)
211. Lei H, Deng CX. 2017 Fibroblast growth factor receptor 2 signaling in breast cancer. *Int. J. Biol. Sci.* **13**, 1163–1171. (doi:10.7150/ijbs.20792)
212. Huang YL, Chou WC, Hsiung CN, Hu LY, Chu HW, Shen CY. 2015 FGFR2 regulates Mre11 expression and double-strand break repair via the MEK-ERK-POU1F1 pathway in breast tumorigenesis. *Hum. Mol. Genet.* **24**, 3506–3517. (doi:10.1093/hmg/ddv102)
213. Moffa AB, Ethier SP. 2007 Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. *J. Cell Physiol.* **210**, 720–731. (doi:10.1002/jcp.20880)
214. Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y, Liang X, Sun Q, Pang D. 2012 Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. *J. Surg. Oncol.* **105**, 773–779. (doi:10.1002/jso.22120)
215. Czaplinska D, Mieczkowski K, Supernat A, Skladanowski AC, Kordek R, Biernat W, Zaczek AJ, Romanska HM, Sadej R. 2016 Interactions between FGFR2 and RSK2—implications for breast cancer prognosis. *Tumour Biol.* **37**, 13 721–13 731. (doi:10.1007/s13277-016-5266-9)
216. Wei W, Liu W, Serra S, Asa SL, Ezzat S. 2015 The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation. *Oncogene* **2015**, 1–9. (doi:10.1038/onc.2014.440)
217. Azuma K *et al.* 2011 Switching additions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. *Biochem. Biophys. Res. Commun.* **407**, 219–224. (doi:10.1016/j.bbrc.2011.03.002)
218. Chew NJ *et al.* 2020 FGFR3 signaling and function in triple negative breast cancer. *Cell Commun. Signal.* **18**, 13. (doi:10.1186/s12964-019-0486-4)
219. Cerliani JP *et al.* 2012 Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer. *Breast Cancer Res. Treat.* **133**, 997–1008. (doi:10.1007/s10549-011-1883-6)
220. Tomlinson DC, Knowles MA, Speirs V. 2012 Mechanisms of FGFR3 actions in endocrine resistant breast cancer. *Int. J. Cancer* **130**, 2857–2866. (doi:10.1002/ijc.26304)
221. Levine KM *et al.* 2019 FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. *NPJ Breast Cancer* **5**, 19. (doi:10.1038/s41523-019-0114-x)
222. Levine KM, Ding K, Chen L, Oesterreich S. 2020 FGFR4: a promising therapeutic target for breast cancer and other solid tumors. *Pharmacol. Ther.* **214**, 107590. (doi:10.1016/j.pharmthera.2020.107590)
223. Cejalvo JM *et al.* 2017 Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. *Cancer Res.* **77**, 2213–2221. (doi:10.1158/0008-5472.CAN-16-2717)
224. Meijer D, Sieuwerts AM, Look MP, van Agthoven T, Foekens JA, Dorsers LC. 2008 Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. *Endocr. Relat. Cancer* **15**, 101–111. (doi:10.1677/ERC-07-0080)
225. Parsons J, Francavilla C. 2019 ‘Omics approaches to explore the breast cancer landscape. *Front. Cell Dev. Biol.* **7**, 395. (doi:10.3389/fcell.2019.00395)
226. Koziczak M, Hynes NE. 2004 Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. *J. Biol. Chem.* **279**, 50 004–50 011. (doi:10.1074/jbc.M404252200)
227. Tiong KH *et al.* 2016 Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. *Oncotarget* **7**, 57 633–57 650. (doi:10.18632/oncotarget.9328)
228. Luo Y, Yang C, Ye M, Jin C, Abbruzzese JL, Lee MH, Yeung SC, McKeenan WL. 2013 Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations. *Cancer Metab.* **1**, 21. (doi:10.1186/2049-3002-1-21)
229. Dallol A *et al.* 2015 Frequent methylation of the KLOTHO gene and overexpression of the FGFR4 receptor in invasive ductal carcinoma of the breast. *Tumour Biol.* **36**, 9677–9683. (doi:10.1007/s13277-015-3733-3)
230. Xu M, Chen S, Yang W, Cheng X, Ye Y, Mao J, Wu X, Huang L, Ji J. 2018 FGFR4 links glucose metabolism and chemotherapy resistance in breast cancer. *Cell Physiol. Biochem.* **47**, 151–160. (doi:10.1159/000489759)
231. Gluz O *et al.* 2020 Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: primary translational analysis of the WSG-ADAPT-TN trial. *Int. J. Cancer* **146**, 262–271. (doi:10.1002/ijc.32488)
232. Zhang Y, Zeng X, Liu P, Hong R, Lu H, Ji H, Lu L, Li Y. 2017 Association between FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphism and breast cancer susceptibility: a meta-analysis. *Oncotarget* **8**, 3454–3470. (doi:10.18632/oncotarget.13839)
233. Woodward ER, van Veen EM, Evans DG. 2021 From BRCA1 to polygenic risk scores: mutation-associated risks in breast cancer-related genes. *Breast Care (Basel)* **16**, 202–213. (doi:10.1159/000515319)
234. Sung VVC *et al.* 2021 Co-dependency for MET and FGFR1 in basal triple-negative breast cancers. *NPJ Breast Cancer* **7**, 36. (doi:10.1038/s41523-021-00238-4)
235. Babina IS, Turner NC. 2017 Advances and challenges in targeting FGFR signalling in cancer. *Nat. Rev. Cancer* **17**, 318–332. (doi:10.1038/nrc.2017.8)
236. Santolla MF, Maggiolini M. 2020 The FGF/FGFR system in breast cancer: oncogenic features and therapeutic perspectives. *Cancers (Basel)* **12**, 3029. (doi:10.3390/cancers12103029)
237. Chae YK *et al.* 2020 Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH Trial (EAY131) subprotocol W. *J. Clin. Oncol.* **38**, 2407–2417. (doi:10.1200/JCO.19.02630)
238. Liu J *et al.* In press. The Smad4-MY018A-PP1A complex regulates β -catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma. *Cell Death Differ.* (doi:10.1038/s41418-021-00897-7)
239. Schuler M *et al.* 2019 Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. *Lancet Oncol.* **20**, 1454–1466. (doi:10.1016/S1470-2045(19)30412-7)
240. Evans KW *et al.* 2021 Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer. *Cancer Res.* **81**, 5572–5581. (doi:10.1158/0008-5472.CAN-20-3242)
241. Musolino A *et al.* 2017 Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR⁺, HER2⁻ breast cancer that had progressed during or after prior endocrine therapy. *Breast Cancer Res.* **19**, 18. (doi:10.1186/s13058-017-0807-8)
242. Campone M *et al.* 2019 A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer. *Cancer Chemother. Pharmacol.* **83**, 743–753. (doi:10.1007/s00280-018-03765-3)
243. Du Z, Lovly CM. 2018 Mechanisms of receptor tyrosine kinase activation in cancer. *Mol. Cancer.* **17**, 58. (doi:10.1186/s12943-018-0782-4)
244. Abou-Faycal C, Hatat AS, Gazzeri S, Eymin B. 2017 Splice variants of the RTK family: their role in tumour progression and response to targeted therapy. *Int. J. Mol. Sci.* **18**, 383. (doi:10.3390/ijms18020383)
245. Bellot F, Crumley G, Kaplow JM, Schlessinger J, Jaye M, Dionne CA. 1991 Ligand-induced transphosphorylation between different FGF receptors. *EMBO J.* **10**, 2849–2854. (doi:10.1002/j.1460-2075.1991.tb07834.x)

246. Johnston CL, Cox HC, Gomm JJ, Coombes RC. 1995 Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. *J. Biol. Chem.* **270**, 30 643–30 650. (doi:10.1074/jbc.270.51.30643)
247. Zammit C, Barnard R, Gomm J, Coope R, Shousha S, Coombes C, Johnston C. 2001 Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. *J. Pathol.* **194**, 27–34. (doi:10.1002/path.846)
248. Yan G, Fukabori Y, McBride G, Nikolaropoulos S, McKeehan WL. 1993 Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. *Mol. Cell Biol.* **13**, 4513–4522. (doi:10.1128/mcb.13.8.4513-4522.1993)
249. Cha JY, Lambert QT, Reuther GW, Der CJ. 2008 Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. *Mol. Cancer Res.* **6**, 435–445. (doi:10.1158/1541-7786.MCR-07-0187)
250. Rebecca VW, Smalley KS. 2014 Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. *Biochem. Pharmacol.* **91**, 417–425. (doi:10.1016/j.bcp.2014.07.031)
251. Katoh M. 2016 Therapeutics targeting FGF signaling network in human diseases. *Trends Pharmacol. Sci.* **37**, 1081–1096. (doi:10.1016/j.tips.2016.10.003)
252. Liu Z *et al.* 2016 Binding of human recombinant mutant soluble ectodomain of FGFR2IIIc to c subtype of FGFRs: implications for anticancer activity. *Oncotarget* **7**, 68 473–68 488. (doi:10.18632/oncotarget.12067)
253. van Brummelen EMJ *et al.* 2020 A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. *Invest. New Drugs* **38**, 457–467. (doi:10.1007/s10637-019-00783-7)
254. Zhang J, Li Y. 2016 Therapeutic uses of FGFs. *Semin. Cell Dev. Biol.* **53**, 144–154. (doi:10.1016/j.semcdb.2015.09.007)
255. Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, Chen HZ, Roychowdhury S. 2021 Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. *Br. J. Cancer* **124**, 880–892. (doi:10.1038/s41416-020-01157-0)
256. Wu YM *et al.* 2013 Identification of targetable FGFR gene fusions in diverse cancers. *Cancer Discov.* **3**, 636–647. (doi:10.1158/2159-8290.CD-13-0050)